https://trial.medpath.com/news/compremium-launches-first-in-human-study-of-non-invasive-thyroid-cancer-diagnostic-device 2025-07-16T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-whoop-over-unapproved-blood-pressure-feature 2025-07-16T01:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/omniscope-pioneers-immune-profiling-breakthrough-for-personalized-pediatric-cancer-therapy 2025-07-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-votes-against-gsk-s-blenrep-for-multiple-myeloma-over-eye-safety-concerns 2025-07-15T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/csl-consolidates-r-d-operations-to-six-global-hubs-in-strategic-shift-toward-external-partnerships 2025-07-15T21:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-secures-patent-extension-for-gedatolisib-through-2042-strengthening-breast-cancer-drug-portfolio 2025-07-15T21:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-secures-international-patents-for-cypath-lung-cancer-diagnostic-in-china-and-canada 2025-07-15T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-pharmaceutical-industry-faces-patent-suspension-threat-amid-u-s-trade-tensions 2025-07-15T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-halol-plant-fails-another-fda-inspection-over-contamination-concerns 2025-07-15T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-raises-eye-safety-concerns-for-gsk-s-blenrep-ahead-of-advisory-committee-review 2025-07-15T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/egetis-therapeutics-advances-toward-us-nda-submission-for-tiratricol-following-fda-breakthrough-therapy-designation 2025-07-15T21:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/evestia-clinical-merges-with-atlantic-research-group-to-create-global-specialist-cro 2025-07-15T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/taxis-pharmaceuticals-receives-fda-qidp-designation-for-txa14007-efflux-pump-inhibitor-to-combat-antibiotic-resistant-pneumonia 2025-07-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-kirsty-as-first-interchangeable-rapid-acting-insulin-aspart-biosimilar 2025-07-15T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-shows-anti-aging-properties-in-preclinical-study-extending-cellular-lifespan-by-50 2025-07-15T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/aatec-medical-partners-with-northway-biotech-to-scale-atl-105-production-for-non-cf-bronchiectasis-treatment 2025-07-15T17:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-names-corleen-roche-as-cfo-during-commercial-launch-of-first-fda-approved-til-therapy 2025-07-15T17:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-receives-fda-approval-for-generic-celecoxib-capsules-in-multiple-strengths 2025-07-15T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-study-shows-stem-cell-therapy-enhances-immune-recovery-in-cats-with-coronavirus-offering-insights-for-long-covid-treatment 2025-07-15T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/c-mo-medical-solutions-achieves-iso-13485-certification-for-ai-powered-cough-monitoring-technology 2025-07-15T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-secures-composition-of-matter-patent-for-certepetide-through-2040 2025-07-15T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-mtx-001-selected-as-finalist-for-advanced-wound-care-innovation-showcase 2025-07-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-acquires-lanova-medicines-for-951-million-targeting-pd-1xvegf-cancer-therapies 2025-07-15T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/medera-treats-first-patient-in-groundbreaking-gene-therapy-trial-for-duchenne-muscular-dystrophy-heart-failure 2025-07-15T17:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/tdm-guided-ustekinumab-optimization-shows-superior-long-term-efficacy-in-crohn-s-disease-maintenance-therapy 2025-07-15T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-launches-adamunix-subsidiary-to-address-anti-drug-antibody-challenges-in-protein-therapeutics 2025-07-15T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-linc-launch-world-s-first-commercial-ai-drug-discovery-platform-using-federated-learning-from-16-pharmaceutical-companies 2025-07-15T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/365mc-partners-with-raziel-therapeutics-to-advance-rzl-012-injectable-fat-reduction-treatment-in-south-korea 2025-07-15T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-enables-kidney-transplant-patients-to-live-drug-free-for-over-two-years 2025-07-15T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-and-kailera-s-dual-glp-1-gip-obesity-drug-achieves-18-weight-loss-in-phase-3-trial 2025-07-15T17:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/fred-hutch-launches-national-vanguard-study-to-evaluate-multi-cancer-detection-blood-tests 2025-07-15T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-sh-110-oral-liquid-therapy-for-glioma-treatment 2025-07-15T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiota-emerges-as-key-therapeutic-target-for-osteoporosis-through-novel-gut-bone-axis 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-antibacterial-implant-materials-show-promise-against-bone-infections 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-stromal-immunosuppressive-barrier-in-gastric-cancer-that-drives-treatment-resistance 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-models-achieve-perfect-accuracy-in-early-childhood-diabetes-prediction-using-gene-expression-biomarkers 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/menin-inhibitors-market-poised-for-strong-growth-as-revuforj-becomes-first-fda-approved-drug-in-class 2025-07-15T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-danish-study-finds-no-link-between-aluminum-in-childhood-vaccines-and-chronic-diseases 2025-07-15T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-and-buhlmann-launch-rapid-gastrointestinal-biomarker-assays-for-ibd-and-pancreatic-insufficiency-diagnosis 2025-07-15T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/us-maternal-mortality-crisis-deepens-as-deaths-nearly-double-during-pandemic-commonwealth-fund-analysis-reveals 2025-07-15T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-partners-with-jcr-to-develop-enhanced-brain-delivery-therapy-for-alzheimer-s-disease 2025-07-15T13:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/4teen4-s-procizumab-shows-first-in-human-evidence-of-shock-reversal-in-terminally-ill-patients 2025-07-15T13:22:32+00:00 hourly 0.9 https://trial.medpath.com/news/oncomatryx-secures-eur12-5-million-eic-accelerator-funding-to-advance-novel-adc-platform-for-hard-to-treat-cancers 2025-07-15T13:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/follicular-lymphoma-market-poised-for-6-cagr-growth-through-2034-as-novel-therapies-advance 2025-07-15T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-to-hope-trial-shows-hope-reduces-liver-transplant-costs-by-28565-and-severe-rejection-rates 2025-07-15T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-treatment-pipeline-advances-with-extended-release-formulations-from-weekly-to-annual-dosing 2025-07-15T09:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/korean-researchers-develop-precision-nanobody-therapy-for-lung-adenocarcinoma-with-90-tumor-reduction 2025-07-15T09:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biodynamics-episwitch-biomarkers-show-promise-in-pfizer-bladder-cancer-trial 2025-07-15T09:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/synendos-therapeutics-names-dr-george-garibaldi-as-cmo-to-lead-phase-2-development-of-novel-neuropsychiatric-therapy 2025-07-15T09:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/mit-and-ucsb-researchers-develop-light-activated-platform-to-discover-broad-spectrum-antiviral-compounds 2025-07-15T09:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-partners-with-lynx-analytics-to-accelerate-ai-driven-drug-discovery-for-sarcopenia 2025-07-15T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-funding-cuts-could-trigger-14-million-deaths-and-devastating-tb-crisis-by-2030 2025-07-15T08:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/heart-failure-pipeline-shows-strong-growth-with-75-therapies-in-development-across-70-companies 2025-07-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/avacopan-demonstrates-superior-safety-profile-in-anca-associated-vasculitis-across-multiple-clinical-trials 2025-07-15T06:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-nppa-sets-retail-prices-for-71-essential-drug-formulations-including-cancer-and-diabetes-medications 2025-07-15T05:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-irrigation-rate-for-johnson-johnson-s-varipulse-pulsed-field-ablation-platform 2025-07-15T05:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-transforms-aml-treatment-strategy-as-mrd-testing-guides-transplant-decisions 2025-07-15T05:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/telemedicine-transforms-oncology-care-with-86-of-cancer-specialists-calling-virtual-visits-essential 2025-07-15T03:54:52+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-pharmacists-lead-biosimilar-integration-strategies-to-optimize-cancer-care-access-and-costs 2025-07-15T02:54:57+00:00 hourly 0.9 https://trial.medpath.com/news/anti-nausea-drug-aprepitant-shows-significant-survival-benefits-in-triple-negative-breast-cancer 2025-07-15T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/nostrum-laboratories-recalls-sucralfate-tablets-following-bankruptcy-and-operational-shutdown 2025-07-15T01:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-seeks-fda-mums-designation-for-first-oral-canine-babesiosis-treatment 2025-07-15T01:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/unibar-corporation-secures-european-patent-for-capsiclear-eye-health-ingredient-targeting-glaucoma-treatment 2025-07-15T01:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-naturally-restore-testosterone-levels-in-men-with-obesity-and-type-2-diabetes 2025-07-15T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/simulations-plus-invests-1-million-in-clinical-trial-technology-company-nurocor 2025-07-15T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-drugs-remain-effective-despite-treatment-interruptions-when-combined-with-lifestyle-changes 2025-07-15T01:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/whoop-challenges-fda-classification-of-blood-pressure-monitoring-feature-as-medical-device 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/head-to-head-trial-compares-risankizumab-and-vedolizumab-in-treatment-naive-ulcerative-colitis-patients 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bsa-encapsulated-morin-hydrate-nanoparticles-show-enhanced-anticancer-activity-against-colorectal-cancer 2025-07-14T21:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/kaizen-biosciences-advances-pediatric-antibiotic-formulation-with-reduced-clavulanate-for-infants 2025-07-14T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-initiates-first-clinical-trial-of-topical-il-36-inhibitor-gx-03-for-moderate-to-severe-eczema 2025-07-14T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-s-primec-shows-33-reduction-in-als-disease-progression-in-phase-2b-trial 2025-07-14T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/uaeu-researcher-secures-four-patents-for-computational-drug-design-and-medical-device-innovations 2025-07-14T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/kenvue-ceo-thibaut-mongon-steps-down-as-consumer-health-company-undergoes-strategic-review 2025-07-14T17:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-monthly-contraceptive 2025-07-14T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-identify-gut-bacteria-strain-that-enhances-cancer-immunotherapy-effectiveness 2025-07-14T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/avalon-globocare-secures-hong-kong-patent-for-bispecific-car-t-and-car-nk-cell-technology 2025-07-14T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-extends-evkeeza-approval-to-infants-as-young-as-6-months-for-rare-cholesterol-disorder 2025-07-14T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/sonnet-biotherapeutics-pivots-to-cryptocurrency-with-888-million-hype-token-treasury-strategy 2025-07-14T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-launches-deuruxolitinib-for-severe-alopecia-areata-in-us-market 2025-07-14T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-secures-strategic-investment-to-expand-biotherapeutics-manufacturing-capabilities 2025-07-14T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/endometriosis-pain-treatment-pipeline-shows-mixed-results-as-nhs-approves-first-daily-oral-therapy 2025-07-14T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/uniquity-bio-appoints-will-kane-as-ceo-to-lead-anti-tslp-therapy-through-phase-iii-development 2025-07-14T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-abandons-depression-drug-esmethadone-after-three-failed-phase-iii-trials 2025-07-14T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/essa-pharma-agrees-to-1-91-per-share-acquisition-by-xenotherapeutics-in-wind-down-transaction 2025-07-14T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-inc-submits-fda-application-for-radiogel-hydrogel-based-cancer-therapy 2025-07-14T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-expands-generic-license-for-long-acting-hiv-treatment-to-133-countries 2025-07-14T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/indiana-university-receives-11-3-million-nih-grant-to-advance-ship1-inhibitor-for-alzheimer-s-disease 2025-07-14T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/waters-corporation-and-bd-announce-17-5-billion-merger-to-create-life-sciences-and-diagnostics-leader 2025-07-14T13:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/illimis-therapeutics-secures-42m-series-b-to-advance-gaia-platform-for-alzheimer-s-and-immune-disease-treatments 2025-07-14T13:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-raises-192m-in-oversubscribed-share-placement-to-advance-cancer-pipeline 2025-07-14T13:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/ztz-bio-secures-fourth-global-big-pharma-partnership-for-long-acting-injectable-drug-development 2025-07-14T08:57:31+00:00 hourly 0.9 https://trial.medpath.com/news/cures-within-reach-launches-100000-grant-program-for-ai-driven-drug-repurposing-clinical-trials 2025-07-14T08:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-reports-75-response-rate-in-diffuse-large-b-cell-lymphoma-trial 2025-07-14T08:56:59+00:00 hourly 0.9 https://trial.medpath.com/news/antimalarial-drug-efficacy-remains-high-in-mozambique-and-liberia-despite-regional-resistance-concerns 2025-07-14T08:56:55+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-s-azer-cel-achieves-75-response-rate-in-phase-1b-trial-for-relapsed-dlbcl 2025-07-14T04:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-secures-european-patent-protection-for-gpc3-targeted-car-t-therapy-following-successful-defense-at-epo 2025-07-14T04:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/uk-and-vietnam-strike-ps250-million-pharmaceutical-trade-deal-to-accelerate-medicine-registration 2025-07-14T04:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/genomill-health-s-bridge-capture-technology-matches-gold-standard-sensitivity-for-liquid-biopsy-in-metastatic-colorectal-cancer 2025-07-14T03:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-developed-cancer-drug-prl3-zumab-shows-promise-for-treating-vision-loss-in-amd-and-diabetic-retinopathy 2025-07-14T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/implanted-vagus-nerve-stimulation-device-shows-promise-for-treatment-resistant-rheumatoid-arthritis 2025-07-13T21:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/100-orange-juice-shows-no-blood-sugar-impact-in-type-2-diabetes-patients-clinical-trial-reveals 2025-07-13T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/functional-nanomaterials-advance-photothermal-therapy-for-cancer-treatment 2025-07-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/two-decades-of-nk-cell-trials-show-promise-for-aml-treatment-with-37-complete-remission-rate 2025-07-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-receives-cdsco-approval-for-phase-iii-rsv-vaccine-trial-in-india-with-conditional-requirements 2025-07-13T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-plans-entry-into-india-s-weight-management-market-as-obesity-becomes-strategic-priority 2025-07-13T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-aid-cuts-halt-hiv-vaccine-research-in-south-africa-threatening-global-progress 2025-07-13T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-validates-fingerprint-sweat-testing-for-drug-detection-with-pharmacokinetic-study-data 2025-07-13T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/elegen-and-nutcracker-therapeutics-launch-industry-s-first-fully-cell-free-manufacturing-platform-for-rna-based-personalized-cancer-therapeutics 2025-07-13T05:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-biontech-advance-phase-2-trial-combining-cancer-vaccine-bnt116-with-cemiplimab-for-advanced-nsclc 2025-07-13T01:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-receive-950000-grant-to-launch-multi-institutional-trial-of-zipalertinib-for-egfr-mutated-cancers 2025-07-13T01:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/ripretinib-shows-comparable-survival-to-sunitinib-in-advanced-gist-with-improved-safety-profile 2025-07-12T21:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/cel-sci-raises-5-7m-to-fund-pivotal-multikine-trial-for-head-and-neck-cancer 2025-07-12T21:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/profusa-goes-public-on-nasdaq-with-tissue-integrating-biosensor-platform-for-chronic-disease-management 2025-07-12T21:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-persistent-gaps-in-molecular-testing-and-targeted-therapy-implementation-for-aml-and-mds 2025-07-12T21:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/simbiosys-receives-third-fda-clearance-for-ai-powered-breast-cancer-surgery-platform-tumorsight-viz 2025-07-12T21:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-medicare-coverage-for-renal-denervation-devices-to-treat-uncontrolled-hypertension 2025-07-12T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/indian-regulators-reject-troikaa-s-rapid-iv-paracetamol-bolus-over-safety-and-efficacy-concerns 2025-07-12T17:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-biosciences-raises-rs-1016-crore-from-anchor-investors-ahead-of-rs-3395-crore-ipo 2025-07-12T17:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-initiates-long-term-gene-modified-t-cell-therapy-safety-study 2025-07-12T17:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/photodynamic-therapy-shows-promise-in-cancer-treatment-with-global-market-expected-to-reach-6-billion-by-2030 2025-07-12T17:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/karyopharm-therapeutics-cuts-20-of-workforce-as-strategic-alternative-search-stalls 2025-07-12T13:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-initiates-real-world-study-of-koselugo-in-korean-patients-to-fulfill-post-approval-commitment 2025-07-12T13:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-successfully-integrated-as-external-control-arm-in-her2-breast-cancer-trial 2025-07-12T13:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-ultragenyx-gene-therapy-for-sanfilippo-syndrome-over-manufacturing-concerns 2025-07-12T09:20:22+00:00 hourly 0.9 https://trial.medpath.com/news/simris-group-adc-partnership-falls-through-as-eu-partner-withdraws-following-strategic-review 2025-07-12T09:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-achieves-complete-cancer-remission-with-off-the-shelf-inkt-cell-therapy 2025-07-12T09:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/gabapentin-linked-to-increased-dementia-risk-in-chronic-pain-patients 2025-07-12T09:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/darolutamide-gains-fda-approval-for-metastatic-hormone-sensitive-prostate-cancer-following-aranote-trial-success 2025-07-12T09:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/independent-pharmacy-owner-develops-structured-career-advancement-model-for-pharmacy-technicians 2025-07-12T09:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-transform-biliary-tract-cancer-treatment-landscape-with-fgfr2-inhibitors-leading-clinical-advances 2025-07-12T09:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-ultragenyx-s-ux111-gene-therapy-for-sanfilippo-syndrome-type-a 2025-07-12T09:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/early-molecular-milestones-critical-for-treatment-free-remission-success-in-chronic-myeloid-leukemia 2025-07-12T09:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-confirm-ivosidenib-efficacy-in-idh1-mutated-cholangiocarcinoma 2025-07-12T09:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/global-biotechnology-market-projected-to-reach-5-71-trillion-by-2034-driven-by-ai-powered-drug-discovery-and-tissue-engineering 2025-07-12T02:56:31+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-health-mart-expands-clinical-services-strategy-with-focus-on-chronic-care-management-and-pharmacogenomics 2025-07-12T02:55:17+00:00 hourly 0.9 https://trial.medpath.com/news/nontargeted-hcv-screening-in-emergency-departments-identifies-34-more-new-infections-than-risk-based-approach 2025-07-12T02:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-system-faces-sustainability-crisis-as-costs-soar-and-workforce-shrinks 2025-07-12T02:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-launches-micro-access-pharmacy-initiative-to-combat-pharmacy-deserts-in-underserved-communities 2025-07-11T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/variational-ai-partners-with-merck-in-349-million-ai-drug-discovery-collaboration 2025-07-11T20:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-phase-iii-trial-shows-low-risk-thyroid-cancer-patients-can-safely-skip-radioiodine-ablation-after-surgery 2025-07-11T20:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/ema-lifts-age-restriction-on-valneva-s-chikungunya-vaccine-after-safety-review 2025-07-11T20:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-exits-us-generics-business-to-focus-on-novel-antibiotic-drug-discovery 2025-07-11T20:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-appoints-dr-islam-mohamed-as-scientific-advisory-board-chair-to-advance-oncology-pipeline 2025-07-11T20:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-viral-car-t-therapy-ap8901-enters-phase-i-trial-for-ephb4-positive-solid-tumors 2025-07-11T16:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-receives-6-million-grant-installment-for-smart-drug-delivery-platform-development 2025-07-11T16:59:42+00:00 hourly 0.9 https://trial.medpath.com/news/microsoft-launches-bioemu-ai-system-to-accelerate-drug-discovery-through-protein-simulation 2025-07-11T16:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/brenig-therapeutics-appoints-new-leadership-and-expands-parkinson-s-disease-pipeline-with-nlrp3-inhibitor-acquisition 2025-07-11T16:56:26+00:00 hourly 0.9 https://trial.medpath.com/news/scalp-cooling-combined-with-antioxidants-shows-promise-for-preventing-chemotherapy-induced-hair-loss 2025-07-11T16:55:58+00:00 hourly 0.9 https://trial.medpath.com/news/intuitive-receives-fda-clearance-for-vessel-sealer-curved-first-advanced-energy-instrument-approved-for-lymphatic-vessel-transection 2025-07-11T16:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/precigen-stock-surges-48-84-following-positive-fda-designations-for-gene-therapy-pipeline 2025-07-11T15:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/biologic-therapies-show-favorable-cancer-safety-profile-in-psoriatic-disease-patients 2025-07-11T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-reports-complete-remission-in-metastatic-testicular-cancer-patient-using-allogeneic-inkt-cell-therapy 2025-07-11T14:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-reports-positive-phase-1-results-for-novel-kcnk13-inhibitor-cvn293-targeting-neuroinflammation 2025-07-11T13:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/i-peace-and-vita-therapeutics-partner-to-develop-universal-ips-cells-for-fshd-treatment 2025-07-11T13:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-class-ii-risk-warning-for-ritz-peanut-butter-crackers-due-to-mislabeling-that-could-trigger-life-threatening-allergic-reactions 2025-07-11T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-considers-dismantling-u-s-preventive-services-task-force-raising-healthcare-access-concerns 2025-07-11T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/sequoia-trial-data-reveals-sustained-responses-with-zanubrutinib-in-high-risk-cll-patients 2025-07-11T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wacker-opens-new-biotechnology-center-in-munich-to-accelerate-biopharmaceutical-research 2025-07-11T11:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/vsy-biotechnology-s-sinusoidal-trifocal-iol-technology-receives-japanese-approval 2025-07-11T11:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/australian-first-seek-and-destroy-cancer-therapy-begins-human-trials-targeting-cdcp1-protein 2025-07-11T10:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-parp-inhibitor-shows-80-tumor-reduction-in-ebv-driven-lymphoma 2025-07-11T10:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/wireless-nfc-implant-delivers-chemotherapy-deep-into-tumors-with-four-fold-improved-efficiency 2025-07-11T10:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/australian-scientists-develop-real-time-ultrasound-imaging-system-to-enhance-brain-drug-delivery 2025-07-11T09:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-therapeutics-raises-ps1m-to-accelerate-ai-driven-cns-drug-discovery-for-depression-and-stimulant-addiction 2025-07-11T09:18:48+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-victoria-funds-breakthrough-alzheimer-s-research-projects-targeting-prevention-and-treatment 2025-07-11T09:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-protein-degradation-emerges-as-multi-billion-dollar-therapeutic-frontier-with-first-protac-approval-expected-in-2026 2025-07-11T08:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/brecadd-chemotherapy-preserves-fertility-better-than-standard-treatment-in-advanced-hodgkin-s-lymphoma 2025-07-11T08:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/hydrogels-emerge-as-next-generation-platform-for-precision-cancer-drug-delivery 2025-07-11T08:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/bbot-completes-382-million-spac-merger-to-advance-next-generation-ras-targeted-cancer-therapeutics 2025-07-11T07:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/onetouch-pat-breast-imaging-system-demonstrates-promise-in-early-clinical-tests-with-ai-enhanced-detection 2025-07-11T06:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-and-acumen-advance-alzheimer-s-research-with-long-term-data-and-novel-targeting-approaches-at-aaic-2025 2025-07-11T05:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-receives-fda-fast-track-designation-for-ctx-009-bispecific-antibody 2025-07-11T05:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-mandates-online-submission-for-cell-and-gene-therapy-clinical-trial-applications 2025-07-11T05:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/hku-launches-gene-therapy-clinical-trial-for-chronic-hepatitis-b-cure 2025-07-11T05:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/lodestar-study-marks-first-tumor-agnostic-trial-of-parp-inhibitor-rucaparib-in-hrr-gene-variants 2025-07-11T04:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/tocogaia-tocotrienol-beverage-shows-anti-aging-benefits-in-six-month-clinical-trial 2025-07-11T04:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-ceo-john-houston-announces-retirement-following-protac-breakthrough-success 2025-07-11T04:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-retifanlimab-plus-carboplatin-paclitaxel-for-advanced-anal-cancer-following-podium-303-trial-success 2025-07-11T03:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-technology-expands-beyond-covid-vaccines-into-cancer-and-rare-disease-therapeutics 2025-07-11T03:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-raises-200-million-to-fund-commercialization-of-first-fda-approved-prader-willi-syndrome-therapy 2025-07-11T02:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/careone-concierge-launches-clinical-study-for-fda-breakthrough-alzheimer-s-device 2025-07-11T02:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-genomic-profiling-emerges-as-essential-standard-for-personalized-cancer-treatment 2025-07-11T02:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/global-oncology-cell-therapy-market-projected-to-reach-25-billion-by-2031 2025-07-11T02:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/nalirifox-emerges-as-effective-alternative-to-folfirinox-in-metastatic-pancreatic-cancer-treatment 2025-07-11T02:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/chromophobe-renal-cell-carcinoma-shows-immune-cold-environment-and-poor-response-to-checkpoint-inhibitors 2025-07-11T02:17:37+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-advances-two-multiple-myeloma-trials-with-novel-drug-combinations 2025-07-11T01:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/anti-gpc3-targeted-therapies-market-expands-with-novel-treatment-approaches-for-hepatocellular-carcinoma 2025-07-11T01:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/broken-string-biosciences-and-biolizard-partner-to-develop-ai-powered-safeguide-for-crispr-gene-editing-safety 2025-07-11T00:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-s-setrusumab-phase-3-trial-continues-after-interim-analysis-fails-to-meet-early-termination-threshold 2025-07-11T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-recruits-former-fda-oncology-leader-marc-theoret-as-senior-vp-of-regulatory-strategy 2025-07-11T00:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-year-long-flea-and-tick-injectable-for-dogs 2025-07-11T00:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-technology-secures-patent-protection-for-immcelz-cell-therapy-platform-across-heart-failure-and-type-1-diabetes 2025-07-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/synchrony-medical-receives-fda-510-k-clearance-for-libairty-airway-clearance-system 2025-07-10T23:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/cognition-therapeutics-receives-fda-endorsement-for-alzheimer-s-drug-zervimesine-phase-3-trial-design 2025-07-10T22:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-and-biontech-advance-two-phase-1-2-cancer-trials-testing-novel-antibody-therapies 2025-07-10T22:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-appoints-new-leadership-team-to-advance-mash-drug-lanifibranor-through-phase-3-trial 2025-07-10T22:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/aqtual-raises-31-million-to-advance-novel-cfdna-platform-for-rheumatoid-arthritis-therapy-prediction 2025-07-10T21:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/xylocor-therapeutics-initiates-phase-2b-trial-for-gene-therapy-xc001-in-refractory-angina 2025-07-10T21:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-strengthens-scientific-advisory-board-with-leading-immunologist-ahead-of-phase-3-results 2025-07-10T21:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-reverses-ptab-decision-on-brimonidine-eye-redness-patent-in-landmark-claim-construction-ruling 2025-07-10T21:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/five-new-york-cancer-centers-form-empire-state-cellular-therapy-consortium-to-accelerate-cell-and-gene-therapy-development 2025-07-10T21:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/ut-southwestern-scientists-develop-targeted-gene-therapy-for-alpha-1-antitrypsin-deficiency-using-designer-lipid-nanoparticles 2025-07-10T21:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/cannabinoid-drug-development-accelerates-with-50-companies-advancing-clinical-trials 2025-07-10T21:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-canadian-public-reimbursement-for-cosentyx-in-hidradenitis-suppurativa 2025-07-10T21:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-conducts-real-world-safety-study-for-anticoagulation-reversal-agent-ondexxya 2025-07-10T21:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-appoints-linda-jonsdottir-as-chief-financial-officer 2025-07-10T21:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/baseline-steroid-use-significantly-reduces-immune-checkpoint-inhibitor-effectiveness-in-nsclc-patients 2025-07-10T21:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/pelthos-therapeutics-launches-zelsuvmi-first-fda-approved-at-home-treatment-for-molluscum-contagiosum 2025-07-10T20:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/dymicron-s-diamond-based-cervical-disc-receives-fda-approval-to-begin-u-s-clinical-trial 2025-07-10T20:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-amivantamab-lazertinib-combination-in-advanced-nsclc-treatment 2025-07-10T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/modified-neovax-cancer-vaccine-shows-enhanced-immune-response-in-melanoma-patients 2025-07-10T20:15:05+00:00 hourly 0.9 https://trial.medpath.com/news/il-2-inhibitor-pipeline-expands-with-20-companies-developing-22-therapeutic-candidates 2025-07-10T20:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-and-eledon-partner-to-advance-type-1-diabetes-bio-hybrid-organ-therapy-with-novel-immunosuppression 2025-07-10T20:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/eolas-therapeutics-assumes-full-development-rights-to-first-in-class-orexin-1-receptor-antagonist-azd4041-for-substance-use-disorders 2025-07-10T18:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/niagen-bioscience-secures-exclusive-license-for-nicotinamide-riboside-as-parkinson-s-disease-therapy 2025-07-10T18:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-joins-international-phase-1-trial-testing-car-t-cell-therapy-for-multiple-sclerosis 2025-07-10T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-names-renee-gala-as-ceo-in-strategic-leadership-transition 2025-07-10T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-tsnd-201-for-ptsd-treatment 2025-07-10T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-advances-two-phase-3-and-phase-2-trials-testing-acasunlimab-combinations-in-lung-cancer-and-melanoma 2025-07-10T16:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/fifty1-ai-labs-completes-landmark-phase-iii-revive-trial-for-long-covid-treatment 2025-07-10T16:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/painreform-expands-into-ophthalmology-with-3m-strategic-investment-in-layerbio-s-ocuring-k 2025-07-10T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/zorevunersen-shows-promising-cognitive-and-behavioral-improvements-in-dravet-syndrome-phase-3-trial-analysis 2025-07-10T16:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/sk-capital-enters-exclusive-talks-to-acquire-lisi-medical-in-eur179m-medtech-cdmo-deal 2025-07-10T16:29:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-publishes-over-200-drug-rejection-letters-in-historic-transparency-initiative 2025-07-10T16:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-s-advanced-clareon-panoptix-pro-iol-receives-canadian-approval-for-cataract-surgery 2025-07-10T16:24:19+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-raises-99m-series-b-to-advance-copper-based-radiopharmaceutical-platform 2025-07-10T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/arcus-biosciences-cd73-inhibitor-quemliclustat-receives-fda-orphan-drug-designation-for-pancreatic-cancer 2025-07-10T15:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/radiant-biotherapeutics-appoints-deborah-geraghty-as-president-and-ceo 2025-07-10T15:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/florida-launches-first-in-nation-newborn-genetic-screening-program-with-7-5-million-state-investment 2025-07-10T15:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotech-s-novel-il-12-adc-advances-to-phase-2-stage-2-in-metastatic-colorectal-cancer 2025-07-10T12:56:30+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-supreme-court-petition-could-reshape-patent-obviousness-standards-for-pharmaceutical-industry 2025-07-10T12:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-researchers-achieve-breakthrough-in-immunotherapy-for-metastatic-colon-cancer 2025-07-10T12:55:53+00:00 hourly 0.9 https://trial.medpath.com/news/epitopea-strengthens-leadership-team-as-rna-based-cancer-immunotherapy-platform-advances-toward-clinical-trials 2025-07-10T12:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-enables-mice-to-produce-diabetes-drug-exenatide-for-sustained-weight-control 2025-07-10T12:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/varda-space-industries-secures-187-million-series-c-to-advance-microgravity-drug-manufacturing 2025-07-10T12:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-long-term-amlitelimab-study-for-moderate-to-severe-atopic-dermatitis 2025-07-10T12:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-expands-partnership-with-university-of-sydney-to-accelerate-clinical-trial-innovation 2025-07-10T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/news/tandemai-and-perpetual-medicines-merge-to-advance-ai-driven-small-molecule-and-peptide-drug-discovery 2025-07-10T12:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/renasant-bio-raises-54-5m-to-develop-novel-ion-channel-therapies-for-adpkd 2025-07-10T12:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/renovaro-biosciences-converts-9-7m-debt-to-equity-strengthens-ai-driven-drug-discovery-platform 2025-07-10T12:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-biib080-receives-fda-fast-track-designation-for-alzheimer-s-disease-treatment 2025-07-10T10:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-pharmaceuticals-receives-nmpa-approval-for-local-manufacturing-of-ret-inhibitor-gavreto-in-china 2025-07-10T10:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-critical-gaps-in-lyme-disease-follow-up-care-and-diagnostic-testing 2025-07-10T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-receives-fda-approval-for-strategy-to-lift-clinical-hold-on-als-drug-nuz-001 2025-07-10T09:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/genomenon-and-ucb-partner-to-advance-thymidine-kinase-2-deficiency-diagnosis-through-genomic-intelligence 2025-07-10T09:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-driven-precision-medicine-transforms-treatment-landscape-for-metastatic-castration-sensitive-prostate-cancer 2025-07-10T09:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-completes-enrollment-for-keytruda-biosimilar-study-skips-phase-iii-trial-with-fda-approval 2025-07-10T08:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-non-opioid-painkiller-journavx-faces-access-barriers-despite-fda-approval 2025-07-10T04:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-signatures-predict-immunotherapy-response-in-metastatic-melanoma-patients 2025-07-10T04:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-gains-40-over-five-days-following-fda-ind-clearance-for-cell-therapy-program 2025-07-10T04:58:42+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-receives-fda-fast-track-approval-for-magsense-her2-breast-cancer-imaging-agent 2025-07-10T04:58:30+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-secures-10-million-credit-line-to-advance-mash-cirrhosis-program-through-2026 2025-07-10T03:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-pharmacists-expand-role-in-value-based-care-under-enhanced-oncology-model 2025-07-10T03:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/longevity-biotechs-attract-4-8-billion-investment-as-companies-target-aging-mechanisms-over-life-extension 2025-07-10T03:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/trump-announces-100-tariff-on-branded-pharmaceuticals-starting-october-1-exempts-companies-building-us-plants 2025-07-10T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/progenra-discovers-first-in-class-pink1-activators-for-inherited-parkinson-s-disease 2025-07-10T02:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-secures-fda-alignment-on-accelerated-approval-pathway-for-rilparencel-in-chronic-kidney-disease 2025-07-10T00:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-and-mereo-biopharma-advance-setrusumab-phase-3-studies-for-osteogenesis-imperfecta-toward-year-end-analysis 2025-07-10T00:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-initiates-phase-1-trial-of-novel-m4-receptor-modulator-nmra-861-for-schizophrenia 2025-07-09T22:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/benitec-biopharma-advances-bb-301-gene-therapy-trial-for-opmd-following-positive-safety-review 2025-07-09T21:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/geniphys-receives-fda-510-k-clearance-for-first-in-class-self-assembling-collagen-scaffold-for-wound-care 2025-07-09T21:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/granules-india-recalls-33000-bottles-of-blood-pressure-medication-in-us-due-to-manufacturing-defects 2025-07-09T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-scientists-develop-first-mrna-vaccine-against-bacterial-infection-targeting-plague-pathogen 2025-07-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-taiho-s-application-for-inqovi-venetoclax-combination-in-acute-myeloid-leukemia 2025-07-09T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-setmelanotide-shows-breakthrough-results-in-rare-hypothalamic-obesity-trial 2025-07-09T21:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/ofichem-group-acquires-avivia-to-expand-complex-formulation-development-capabilities 2025-07-09T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/xaira-therapeutics-appoints-jeff-jonker-as-president-and-coo-to-scale-ai-driven-drug-discovery-platform 2025-07-09T20:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-develop-ai-designed-protein-to-combat-antibiotic-resistant-e-coli 2025-07-09T20:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/zhimeng-biopharma-s-cb03-154-receives-chinese-regulatory-approval-for-als-phase-2-3-trial 2025-07-09T20:23:04+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-biosciences-positions-as-china-alternative-in-3-4-billion-ipo-amid-global-supply-chain-shift 2025-07-09T20:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/kolon-tissuegene-expands-tg-c-cell-gene-therapy-to-spinal-indications-with-fda-approval 2025-07-09T20:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-reversing-immune-checkpoint-inhibitor-resistance-across-multiple-cancer-types 2025-07-09T19:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/empagliflozin-demonstrates-cost-effectiveness-in-chronic-kidney-disease-treatment-empa-kidney-analysis-shows 2025-07-09T19:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-tralokinumab-meets-all-endpoints-in-phase-3b-hand-atopic-dermatitis-trial 2025-07-09T18:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/mit-develops-implantable-device-for-automated-glucagon-delivery-to-prevent-diabetic-hypoglycemia 2025-07-09T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-preventing-severe-morning-sickness-in-early-studies 2025-07-09T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-device-algorithm-detects-covid-19-infections-seven-days-earlier-than-symptom-based-screening 2025-07-09T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-stedim-biotech-partners-with-sensible-biotechnologies-to-scale-cell-based-mrna-manufacturing-platform 2025-07-09T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/evoke-pharma-secures-patent-extension-for-gimoti-nasal-spray-extending-market-exclusivity-to-2036 2025-07-09T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-partners-with-fountain-life-to-deploy-stem-cell-therapies-under-new-florida-law 2025-07-09T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/neuros-medical-secures-56-million-series-d-to-commercialize-fda-approved-post-amputation-pain-treatment 2025-07-09T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-coq10-precursor-treatment-shows-dramatic-results-in-8-year-old-with-rare-fatal-disease 2025-07-09T16:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-primula-preg-study-to-evaluate-anifrolumab-safety-during-pregnancy-in-sle-patients 2025-07-09T16:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-exclusive-option-for-sironax-s-blood-brain-barrier-platform-in-175m-deal 2025-07-09T16:29:14+00:00 hourly 0.9 https://trial.medpath.com/news/kala-bio-completes-phase-2b-pced-trial-enrollment-no-fda-approved-options-exist 2025-07-09T16:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/piper-sandler-initiates-overweight-rating-on-inovio-pharmaceuticals-ahead-of-potential-fda-approval-for-ino-3107 2025-07-09T16:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/four-company-consortium-launches-ai-driven-drug-discovery-for-subarachnoid-hemorrhage-complications 2025-07-09T16:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-partners-with-iambic-therapeutics-in-25m-ai-driven-drug-discovery-collaboration-for-ras-addicted-cancers 2025-07-09T16:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/exactech-receives-fda-clearance-for-first-to-market-scapula-reconstruction-system-targeting-post-surgical-fractures 2025-07-09T16:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/spt-labtech-and-semarion-partner-to-automate-cell-based-drug-screening-workflows 2025-07-09T16:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/uk-issues-class-2-recall-for-zaditen-eye-drops-batch-due-to-potential-microbial-contamination-risk 2025-07-09T16:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-appoints-chief-legal-officer-as-company-prepares-fda-filing-for-novel-adhd-treatment 2025-07-09T16:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/suvoda-and-greenphire-complete-merger-to-create-integrated-clinical-trial-technology-platform 2025-07-09T16:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-seclidemstat-gains-validation-as-lsd1-inhibitor-in-new-studies-while-phase-1-2-trial-advances 2025-07-09T14:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-terminates-adc-platform-technology-contract-with-intussell-over-patent-concerns 2025-07-09T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-two-il-23-inhibitors-for-crohn-s-disease-as-gastroenterology-advances-in-2025 2025-07-09T13:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/nature-study-validates-lixte-s-pp2a-inhibitor-lb-100-for-enhanced-cancer-immunotherapy 2025-07-09T13:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-acquires-swiss-packaging-specialist-ivers-lee-to-expand-biosimilar-manufacturing-capacity 2025-07-09T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-quietly-advances-marburg-and-sudan-ebolavirus-vaccine-development-despite-kennedy-s-vaccine-skepticism 2025-07-09T13:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/mattel-launches-first-type-1-diabetes-barbie-doll-with-medical-device-accessories 2025-07-09T13:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/phesi-ceo-warns-of-impending-phase-3-trial-failures-due-to-site-oversaturation-and-complex-design 2025-07-09T12:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/centivax-secures-45-million-series-a-to-advance-universal-flu-vaccine-into-phase-i-clinical-trial 2025-07-09T08:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-secures-50-million-licensing-deal-with-zentiva-for-global-certolizumab-pegol-biosimilar-rollout 2025-07-09T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/dri-scientists-achieve-diabetes-reversal-using-small-peptide-thr-123-in-preclinical-models 2025-07-09T08:54:55+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-seeks-european-approval-to-expand-akeega-for-metastatic-prostate-cancer-with-genetic-alterations 2025-07-09T08:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-servier-launch-first-european-xseed-labs-to-advance-ai-driven-bispecific-antibody-design 2025-07-09T08:18:35+00:00 hourly 0.9 https://trial.medpath.com/news/merck-announces-10-billion-acquisition-of-verona-pharma-to-expand-copd-treatment-portfolio 2025-07-09T08:18:08+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-s-exopten-achieves-100-motor-function-recovery-in-spinal-cord-injury-preclinical-study 2025-07-09T07:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/aktiia-s-hilo-band-becomes-first-fda-cleared-cuffless-blood-pressure-monitor-for-over-the-counter-use 2025-07-09T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/two-new-tuberculosis-drugs-show-superior-safety-profile-over-linezolid-in-phase-2b-trials 2025-07-09T05:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-develops-dual-active-material-science-technology-for-glp-1-drug-protection 2025-07-09T04:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-solutions-advances-targeted-chemotherapy-delivery-platform-to-enhance-precision-oncology 2025-07-09T04:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-testing-and-circulating-tumor-dna-advances-set-to-transform-gist-management 2025-07-09T03:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-meta-analysis-confirms-strong-association-between-alopecia-areata-and-multiple-immune-mediated-disorders 2025-07-09T03:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/medical-organizations-sue-rfk-jr-over-unlawful-covid-19-vaccine-policy-changes 2025-07-09T03:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-launches-varipulsetm-pulsed-field-ablation-platform-across-asia-pacific-for-atrial-fibrillation-treatment 2025-07-09T01:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/cresset-acquires-molab-ai-to-enhance-ai-driven-drug-discovery-platform 2025-07-09T01:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-wins-federal-circuit-appeal-preserves-invega-sustenna-patent-protection-until-2031 2025-07-09T01:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-appoints-chad-spooner-as-cfo-for-minimed-diabetes-spinoff 2025-07-09T00:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-partners-with-conjugatebio-to-develop-novel-bispecific-antibody-drug-conjugates 2025-07-09T00:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/eye-net-achieves-99-detection-rate-in-french-urban-mobility-safety-trial 2025-07-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eluciderm-receives-fda-clearance-for-first-in-human-trial-of-elu42-in-diabetic-foot-ulcers 2025-07-08T23:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-fda-application-to-expand-caplyta-for-schizophrenia-relapse-prevention 2025-07-08T21:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-s-rilparencel-shows-promising-phase-2-results-for-diabetic-kidney-disease 2025-07-08T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/iric-and-ipsen-initiate-phase-1-trial-of-raf-inhibitor-ipn01195-for-solid-tumors 2025-07-08T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/dermata-therapeutics-secures-australian-patent-for-needle-free-botulinum-toxin-hyperhidrosis-treatment 2025-07-08T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-receives-fda-and-health-canada-approval-for-first-in-class-gene-therapy-targeting-fatal-heart-rhythm-disorder 2025-07-08T21:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/georgia-tech-develops-exploding-capsule-technology-for-needle-free-insulin-delivery 2025-07-08T20:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/fziomed-receives-fda-de-novo-authorization-for-oxiplex-gel-in-lumbar-spine-surgery 2025-07-08T20:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/cumulus-neuroscience-raises-ps3-25m-to-transform-neurological-clinical-trials-with-fda-cleared-eeg-technology 2025-07-08T20:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/nyb-ai-and-pnaseer-inc-form-strategic-partnership-to-advance-ai-powered-hair-regeneration-research 2025-07-08T20:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/stampede-trial-shows-metformin-improves-metabolic-health-in-metastatic-prostate-cancer-patients-despite-no-survival-benefit 2025-07-08T19:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/cardio-diagnostics-partners-with-agepha-pharma-to-validate-ai-powered-precision-medicine-approach-for-inflammation-driven-coronary-heart-disease 2025-07-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-acquires-providence-digital-health-spinoff-xealth-to-bridge-consumer-wellness-and-clinical-care 2025-07-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/ciloa-secures-eur6-5-million-french-government-funding-to-advance-novel-adiponectin-based-therapy-for-obesity-and-type-2-diabetes 2025-07-08T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-presents-real-world-data-on-long-acting-hiv-treatments-at-ias-2025 2025-07-08T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/first-nanobody-treatment-shows-promise-against-deadly-nipah-and-hendra-viruses 2025-07-08T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/nobel-peace-prize-laureate-james-orbinski-joins-ai-drug-repurposing-startup-fifty-1-labs 2025-07-08T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-secures-50-million-investment-to-expand-brain-cancer-clinical-trials-in-mena-region 2025-07-08T17:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-partners-with-swog-cancer-research-network-for-ai-driven-small-cell-lung-cancer-precision-medicine-trial 2025-07-08T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/amarna-therapeutics-and-northx-biologics-advance-gene-therapy-for-type-1-diabetes-toward-clinical-trials 2025-07-08T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-cargo-therapeutics-for-202m-following-car-t-trial-failure 2025-07-08T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/champions-oncology-launches-comprehensive-radiopharmaceutical-services-platform-with-expanded-isotope-capabilities 2025-07-08T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-completes-akoya-biosciences-acquisition-creating-integrated-biomarker-detection-platform 2025-07-08T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/eib-provides-eur150-million-to-alfasigma-for-rare-disease-and-specialty-care-innovation 2025-07-08T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-acquires-full-rights-to-rev102-potential-first-in-class-oral-enpp1-inhibitor-for-hypophosphatasia 2025-07-08T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-licenses-just-aav-gene-therapy-platform-to-alexion-in-825-million-deal 2025-07-08T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/certara-expands-clinical-technology-partnership-with-merck-to-streamline-data-management 2025-07-08T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-international-advances-first-plant-based-cannabis-drug-mmj-001-for-huntington-s-disease-chorea 2025-07-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-secures-250k-addf-investment-to-advance-circrna-blood-biomarkers-for-alzheimer-s-diagnosis 2025-07-08T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer-to-lead-next-development-phase 2025-07-08T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/flightpath-biosciences-licenses-microbiome-sparing-antibiotic-lolamicin-for-gram-negative-bacterial-infections 2025-07-08T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/australian-scientists-develop-proteus-biological-ai-platform-to-accelerate-drug-discovery 2025-07-08T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-secures-10m-equity-agreement-to-advance-ai-driven-cancer-drug-discovery 2025-07-08T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-s-pizuglanstat-fails-to-meet-primary-endpoint-in-phase-iii-duchenne-muscular-dystrophy-trial 2025-07-08T16:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/varmx-receives-fda-fast-track-designation-for-vmx-c001-anticoagulant-reversal-therapy 2025-07-08T16:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/mendaera-s-focalist-handheld-robotic-system-receives-fda-clearance-for-ultrasound-guided-procedures 2025-07-08T16:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-validates-ai-powered-blood-test-for-multi-cancer-detection-and-monitoring 2025-07-08T16:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/insightec-receives-fda-approval-for-bilateral-focused-ultrasound-treatment-in-advanced-parkinson-s-disease 2025-07-08T16:17:09+00:00 hourly 0.9 https://trial.medpath.com/news/verified-clinical-trials-launches-advanced-subject-registry-platform-in-japan-to-combat-duplicate-trial-participants 2025-07-08T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/dual-payload-adcs-enter-clinical-testing-as-innovent-and-chengdu-kanghong-pioneer-next-generation-cancer-therapeutics 2025-07-08T16:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-biosciences-launches-3395-crore-ipo-as-contract-research-organization-targets-public-markets 2025-07-08T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-submits-new-drug-application-for-rademikibart-in-china-s-70-million-patient-atopic-dermatitis-market 2025-07-08T16:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/sarilumab-combination-achieves-63-6-response-rate-in-advanced-melanoma-phase-2-trial 2025-07-08T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-pandemic-drove-sharp-rise-in-obesity-among-black-children-and-adolescents-study-finds 2025-07-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-fda-application-for-caplyta-schizophrenia-relapse-prevention-based-on-63-risk-reduction-data 2025-07-08T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-emergency-compassionate-use-of-var-200-for-ultra-rare-apocii-amyloidosis 2025-07-08T12:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/crescent-biopharma-appoints-jan-pinkas-as-chief-scientific-officer-to-advance-oncology-pipeline 2025-07-08T12:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/optibrium-secures-multi-million-pound-financing-to-accelerate-ai-powered-drug-discovery-platform 2025-07-08T12:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-s-rilparencel-shows-78-improvement-in-kidney-function-decline-in-phase-2-ckd-trial 2025-07-08T12:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-briquilimab-shows-89-complete-response-rate-in-csu-despite-manufacturing-setbacks 2025-07-08T12:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/duke-street-bio-receives-fda-fast-track-designation-for-brain-penetrating-parp1-inhibitor-dsb2455 2025-07-08T12:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/veeda-lifesciences-partners-with-mango-sciences-to-deploy-ai-powered-platform-for-enhanced-clinical-trial-diversity 2025-07-08T12:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-expands-fast-track-patent-program-to-20000-applications-annually-as-accelerated-examination-program-ends 2025-07-08T11:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/morphic-medical-receives-ce-mark-for-reset-obesity-device-targeting-alternative-to-bariatric-surgery 2025-07-08T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-secures-39-million-barda-funding-to-advance-novel-antifungal-candidates-fosmanogepix-and-bal2062 2025-07-08T09:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/navamedic-expands-into-addiction-treatment-with-nok-225-million-acquisition-of-dne-pharma 2025-07-08T09:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/biorce-secures-eur5m-to-transform-clinical-trials-with-ai-driven-platform 2025-07-08T09:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-secures-european-patent-protection-for-dha-based-sickle-cell-disease-treatment 2025-07-08T09:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/corbion-gains-chinese-regulatory-approval-for-algae-derived-omega-3-dha-products 2025-07-08T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-receives-approval-for-first-malaria-treatment-designed-for-newborns-and-young-infants 2025-07-08T08:12:23+00:00 hourly 0.9 https://trial.medpath.com/news/kras-g12c-mutations-associated-with-shorter-survival-in-first-line-metastatic-colorectal-cancer-treatment 2025-07-08T08:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/cero-therapeutics-advances-novel-cer-t-cell-therapy-for-aml-with-invivoscribe-diagnostic-support 2025-07-08T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/news/omass-therapeutics-to-present-first-preclinical-data-for-mc2-receptor-antagonist-oms1620-at-endo-2025 2025-07-08T03:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-clinical-launches-cdmo-podcast-series-to-address-drug-development-challenges 2025-07-08T03:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-receives-10-million-milestone-payment-from-cttq-for-mash-drug-development-partnership 2025-07-08T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/medmira-launches-clinical-trial-for-dual-hiv-syphilis-self-test-in-canada 2025-07-08T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-advances-two-first-in-class-antibody-therapies-to-phase-1-trials-following-strategic-pivot 2025-07-08T01:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-strengthens-leadership-team-with-new-cfo-and-senior-vp-appointments 2025-07-08T01:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-xolair-biosimilar-omlyclo-for-allergic-diseases-marking-milestone-in-allergy-treatment-access 2025-07-08T01:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/yiv-906-shows-promising-results-in-phase-2b-trial-for-advanced-hepatocellular-carcinoma-with-hepatitis-b 2025-07-07T23:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-s-art12-11-cocrystal-shows-superior-antidepressant-effects-over-leading-ssri-in-preclinical-study 2025-07-07T22:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-secures-eu-regulatory-harmonization-and-new-patent-for-cancer-radioenhancer-jnj-1900 2025-07-07T21:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-covid-19-vaccines-show-superior-mucosal-immunity-and-long-term-protection-in-preclinical-studies 2025-07-07T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/insurance-disparities-widen-cancer-survival-gaps-despite-immune-checkpoint-inhibitor-advances 2025-07-07T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/pd-l1-expression-correlates-with-hrd-status-and-predicts-survival-in-high-grade-serous-ovarian-cancer 2025-07-07T21:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/aspivix-launches-mhra-approved-carevix-cervical-stabilizer-in-uk-demonstrating-73-pain-reduction-in-iud-procedures 2025-07-07T21:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/blue-lake-and-cyanvac-report-promising-phase-1-results-for-intranasal-covid-19-vaccine-cvxga 2025-07-07T20:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-study-reveals-liver-safety-concerns-with-low-dose-cbd-in-5-of-healthy-adults 2025-07-07T20:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/venture-medical-leads-eur6-million-investment-in-cold-plasma-wound-therapy-developer-plasmacure 2025-07-07T18:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/panther-therapeutics-initiates-phase-1b-trial-of-novel-localized-chemotherapy-film-for-pancreatic-cancer 2025-07-07T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/italy-appoints-special-commissioner-to-fast-track-novo-nordisk-s-2-3-billion-manufacturing-investment 2025-07-07T17:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-reversing-checkpoint-inhibitor-resistance-through-dendritic-cell-activation 2025-07-07T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-key-resistance-mechanism-to-cdk4-6-inhibitors-in-hr-her2-breast-cancer 2025-07-07T16:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/corticosteroids-identified-as-major-factor-limiting-immunotherapy-effectiveness-in-lung-cancer 2025-07-07T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/maplight-therapeutics-initiates-phase-2-trial-of-novel-m1-m4-muscarinic-agonist-ml-007c-ma-for-schizophrenia-treatment 2025-07-07T16:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-s-ff-10832-receives-fda-orphan-drug-designation-for-biliary-tract-cancer-treatment 2025-07-07T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-acquires-lumithera-s-photobiomodulation-device-for-dry-amd-treatment 2025-07-07T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/pace-life-sciences-expands-salem-facility-with-new-aseptic-fill-finish-center-of-excellence 2025-07-07T16:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeat-bio-and-biotx-ai-partner-to-accelerate-heart-failure-drug-discovery-using-ai-and-human-cardiac-organoids 2025-07-07T16:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/synfini-secures-8-9-million-to-accelerate-ai-driven-small-molecule-drug-discovery-platform 2025-07-07T16:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/restore-medical-secures-23m-series-b-to-advance-transcatheter-heart-failure-device-following-fda-breakthrough-designation 2025-07-07T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/sirtex-medical-s-sir-spheres-y-90-resin-microspheres-receive-fda-approval-for-unresectable-hepatocellular-carcinoma 2025-07-07T16:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-mustang-bio-s-mb-101-car-t-therapy-for-brain-cancer-treatment 2025-07-07T16:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/bezuclastinib-achieves-87-response-rate-in-pivotal-trial-for-non-advanced-systemic-mastocytosis 2025-07-07T16:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/orchard-therapeutics-completes-enrollment-in-pivotal-gene-therapy-trial-for-hurler-syndrome 2025-07-07T16:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/biosapien-secures-8-million-in-extended-pre-series-a-round-for-revolutionary-cancer-treatment-platform 2025-07-07T16:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-immune-checkpoint-inhibitor-combinations-show-promise-in-melanoma-treatment 2025-07-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phytogaia-s-tocotrienol-supplement-shows-promise-for-healthy-aging-in-clinical-trial 2025-07-07T15:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-health-authority-approves-theramex-s-abaloparatide-for-high-risk-osteoporosis-treatment 2025-07-07T13:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-appoints-babar-ghias-as-cfo-and-head-of-corporate-development 2025-07-07T13:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-approves-chinese-biosimilar-cancer-drug-to-expand-access-to-affordable-bevacizumab-treatment 2025-07-07T13:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/biosynth-opens-expanded-gmp-bioconjugation-facility-in-berlin-to-support-next-generation-therapeutics 2025-07-07T13:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-and-gero-form-250m-partnership-to-develop-ai-driven-antibody-therapies-for-age-related-diseases 2025-07-07T13:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/als-community-files-citizens-petition-seeking-fda-approval-for-nurown-stem-cell-therapy 2025-07-07T13:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/corflow-therapeutics-receives-fda-approval-for-moca-ii-pivotal-trial-testing-novel-heart-attack-diagnostic-technology 2025-07-07T13:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/eleva-advances-factor-h-therapy-cpv-104-into-first-in-human-trial-for-rare-kidney-disease-c3-glomerulopathy 2025-07-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-implements-capa-at-halol-facility-while-addressing-usfda-compliance-issues-across-three-manufacturing-sites 2025-07-07T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulsesight-therapeutics-doses-first-patient-in-phase-i-trial-of-pst-611-for-dry-amd 2025-07-07T08:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-fat-supplement-shows-promise-in-treating-rare-childhood-disease-ataxia-telangiectasia 2025-07-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-secures-japan-approval-for-pombiliti-opfolda-combination-therapy-for-late-onset-pompe-disease 2025-07-06T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-reveals-therapeutic-potential-of-m6a-regulatory-protein-inhibitors-in-cancer-treatment 2025-07-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/emcure-pharmaceuticals-acquires-full-control-of-zuventus-healthcare-in-724-9-crore-deal 2025-07-06T14:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/thailand-achieves-pharmaceutical-independence-with-first-domestically-produced-targeted-cancer-drugs 2025-07-06T13:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-expert-committee-accepts-pfizer-s-phase-iii-data-for-abrocitinib-in-atopic-dermatitis 2025-07-06T13:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/drdo-and-aiims-rishikesh-partner-for-clinical-trials-of-biomedical-devices-in-extreme-environments 2025-07-06T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-loxo-oncology-advance-phase-3-trial-testing-pirtobrutinib-combination-for-previously-treated-cll-sll 2025-07-06T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/andhra-pradesh-establishes-first-cdsco-notified-medical-device-auditing-body-to-streamline-regulatory-compliance 2025-07-06T00:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-prepares-european-launch-of-subcutaneous-infliximab-biosimilar-following-positive-regulatory-opinion 2025-07-05T20:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-partners-with-children-s-national-hospital-to-advance-pediatric-cell-and-gene-therapy 2025-07-05T09:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-advances-pmx-hemoperfusion-device-toward-fda-approval-for-septic-shock-treatment 2025-07-05T09:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/viemed-healthcare-completes-28m-acquisition-of-lehan-s-medical-equipment-to-expand-respiratory-care-services 2025-07-05T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-multiple-phase-2-trials-targeting-rare-kidney-diseases-and-ulcerative-colitis 2025-07-05T05:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/btk-inhibitors-show-promise-for-progressive-ms-as-current-therapies-fall-short 2025-07-05T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-launches-long-term-safety-study-for-tzield-in-stage-2-type-1-diabetes-patients 2025-07-05T00:40:32+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-raises-75-million-to-advance-firmonertinib-and-cancer-pipeline 2025-07-05T00:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/gallant-raises-18m-to-develop-first-fda-approved-off-the-shelf-stem-cell-therapy-for-pets 2025-07-05T00:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/mcmaster-s-inhaled-covid-19-vaccine-shows-promise-in-phase-1-trials-advances-to-phase-2 2025-07-04T22:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/steep-hill-terminates-acquisition-of-obesity-focused-biotech-lir-life-sciences 2025-07-04T22:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-trial-of-regenerative-cell-therapy-for-sensorineural-hearing-loss-receives-uk-approval 2025-07-04T22:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-us-nasal-covid-19-vaccine-shows-67-infection-reduction-in-phase-1-trial 2025-07-04T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-files-100-million-shelf-prospectus-ahead-of-septic-shock-treatment-milestones 2025-07-04T20:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-launches-generic-ipratropium-bromide-nasal-spray-in-us-market 2025-07-04T20:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-pharma-lifesciences-unit-1-passes-brazilian-anvisa-gmp-inspection-with-no-critical-findings 2025-07-04T17:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/particle-dynamics-acquires-euroapi-uk-spray-drying-facility-to-expand-global-cdmo-capabilities 2025-07-04T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/precisio-biotix-achieves-first-in-human-dosing-of-clyo-lysin-for-multi-drug-resistant-prosthetic-joint-infection 2025-07-04T14:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/serendipity-space-secures-pre-seed-funding-to-advance-microgravity-based-pharmaceutical-manufacturing 2025-07-04T12:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-fabry-disease-shows-promise-with-3-7-million-cost-savings-in-early-stage-trial 2025-07-04T12:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/spineway-secures-gmed-approval-for-new-esp-prostheses-production-line-doubles-manufacturing-capacity 2025-07-04T10:54:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-antibody-treatment-shows-promise-for-hay-fever-prevention-in-preclinical-study 2025-07-04T09:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-advances-ai-powered-mrna-platform-with-cancer-vaccine-breakthroughs 2025-07-04T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-s-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer 2025-07-04T09:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/shimadzu-receives-fda-clearance-for-high-resolution-positview-pet-system-for-alzheimer-s-diagnosis 2025-07-04T08:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/lunit-partners-with-microsoft-to-develop-ai-powered-cancer-diagnostic-tools-on-azure-platform 2025-07-04T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-s-ba3182-shows-tumor-shrinkage-across-multiple-cancer-types-in-phase-1-trial 2025-07-04T06:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-secures-au-5-87-million-r-d-tax-refund-to-advance-immuno-oncology-pipeline 2025-07-04T06:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/brii-biosciences-licenses-novel-antibiotic-brii-693-to-joincare-group-for-greater-china-market 2025-07-04T06:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-casgevy-shows-sustained-efficacy-in-long-term-follow-up-data-for-sickle-cell-disease-and-beta-thalassemia 2025-07-04T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/editas-medicine-achieves-90-ldl-cholesterol-reduction-with-edit-401-gene-therapy-in-preclinical-studies 2025-07-04T06:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-advances-sacituzumab-govitecan-studies-across-multiple-cancer-types 2025-07-04T06:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-s-lanifibranor-shows-promise-in-reversing-liver-vascular-damage-in-mash-patients 2025-07-04T06:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-european-patent-for-novel-anticancer-molecule-targeting-cancer-stem-cells 2025-07-04T05:56:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-thermo-fisher-s-rapid-ngs-companion-diagnostic-for-zegfrovy-in-nsclc 2025-07-04T05:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-s-ai-powered-discovery-engine-expands-molecular-glue-degrader-target-space-in-science-publication 2025-07-04T05:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/fluorescent-drug-bevonescein-shows-promise-for-nerve-sparing-surgery-in-phase-1-2-trial 2025-07-04T05:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/ebenbuild-secures-eur2-3-million-eic-grant-to-advance-digital-twin-platform-for-respiratory-drug-development 2025-07-04T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-acquires-utility-therapeutics-to-commercialize-first-new-uti-antibiotic-in-20-years 2025-07-04T05:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-expands-public-reimbursement-of-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-07-04T05:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-summit-therapeutics-in-advanced-talks-for-15-billion-ivonescimab-licensing-deal 2025-07-04T05:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/mira-s-non-psychoactive-cannabis-analog-mira-55-matches-morphine-s-pain-relief-without-opioid-risks-in-preclinical-study 2025-07-04T05:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/stallergenes-greer-transitions-actair-r-promotional-activities-from-shionogi-to-ceolia-in-japan 2025-07-04T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/eqt-healthcare-growth-acquires-europa-biosite-to-expand-life-sciences-distribution-network 2025-07-04T05:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/stereotaxis-magic-catheter-demonstrates-94-acute-efficacy-in-first-in-human-cardiac-ablation-study 2025-07-04T05:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/iqure-pharma-appoints-former-ucb-chief-medical-officer-iris-loew-friedrich-as-clinical-and-r-d-advisor 2025-07-04T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/rdp-pharma-and-singapore-s-eddc-partner-to-develop-protein-degrader-therapies-for-autoimmune-diseases 2025-07-04T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-and-boehringer-ingelheim-advance-third-oncology-drug-candidate-to-ind-enabling-studies 2025-07-04T04:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/island-pharmaceuticals-raises-6-22-million-to-advance-dengue-fever-treatment-and-antiviral-pipeline 2025-07-04T04:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-secures-global-license-with-elanco-for-als-drug-nuz-001-accelerating-path-to-market 2025-07-04T04:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-receives-fda-approval-for-anaphylm-new-drug-application-targeting-2-billion-severe-allergic-reaction-market 2025-07-04T04:52:21+00:00 hourly 0.9 https://trial.medpath.com/news/integra-lifesciences-launches-pediatric-registry-for-aera-eustachian-tube-balloon-dilation-system 2025-07-04T04:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/auriga-research-partners-with-san-francisco-research-institute-to-advance-ai-driven-clinical-research-across-global-markets 2025-07-04T04:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-ctx310-shows-promising-lipid-reduction-results-in-phase-1-trial 2025-07-04T04:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2025-07-04T04:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/hls-therapeutics-secures-nova-scotia-reimbursement-for-vascepa-expanding-cardiovascular-drug-access-to-95-of-eligible-canadians 2025-07-04T04:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/theratechnologies-agrees-to-254-million-private-acquisition-by-cb-biotechnology 2025-07-04T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharma-receives-ind-acceptance-for-bet-inhibitor-jab-8263-in-autoimmune-diseases 2025-07-04T04:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-completes-phase-3b-asthma-study-evaluating-hfo-mdi-safety-and-launches-china-observational-study 2025-07-04T04:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/norwegian-researchers-report-promising-results-from-daratumumab-pilot-study-in-me-cfs-patients 2025-07-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-raises-115-million-through-secondary-offering-to-fund-pipeline-development 2025-07-03T22:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucomodicum-s-needle-free-cgm-achieves-11-5-mard-in-646-patient-clinical-trial-nears-eu-regulatory-filing 2025-07-03T04:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-blocks-mass-layoffs-at-hhs-citing-likely-unlawful-staff-cuts 2025-07-03T04:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-triple-combination-hypertension-pill-as-june-2025-delivers-major-cardiovascular-advances 2025-07-03T04:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-safety-alert-for-abiomed-blood-pump-controllers-following-three-patient-deaths 2025-07-03T01:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tiancimycin-based-antibody-drug-conjugate-shows-promise-against-aggressive-lymphoma 2025-07-03T01:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-receive-3-5-million-nih-grant-to-develop-novel-mpox-antivirals-targeting-immune-evasion 2025-07-03T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-ai-powered-wristband-for-essential-tremor-treatment 2025-07-03T00:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-indigenous-dengue-vaccine-phase-3-trial-with-over-10000-participants 2025-07-03T00:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-acquires-cantargia-s-can10-antibody-program-for-33-million-upfront-in-autoimmune-disease-deal 2025-07-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/philips-receives-fda-clearance-for-ai-powered-mri-software-that-accelerates-scans-by-3x 2025-07-02T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/bxcl701-plus-pembrolizumab-shows-early-promise-in-second-line-pancreatic-cancer-treatment 2025-07-02T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-gepotidacin-receives-fda-priority-review-for-gonorrhea-treatment 2025-07-02T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/novel-royalty-based-investment-fund-proposes-new-model-for-als-drug-development 2025-07-02T20:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/regener-eyes-receives-fda-closure-of-voluntary-recall-returns-to-full-operations-with-enhanced-safety-features 2025-07-02T20:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-forms-spear-study-group-to-investigate-monoclonal-antibody-therapy-for-long-covid 2025-07-02T20:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/headlands-research-expands-to-caribbean-with-cmrcenter-acquisition-enhancing-hispanic-patient-access-to-clinical-trials 2025-07-02T20:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/argon-ai-secures-5-5m-to-transform-pharmaceutical-data-management-with-ai-native-workspace 2025-07-02T20:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-orders-cdsco-to-review-safety-of-glp-1-diabetes-drugs-used-for-weight-loss 2025-07-02T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-and-shionogi-form-strategic-partnership-to-develop-novel-ntm-treatments-worth-up-to-chf-484-million 2025-07-02T17:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/epo-and-upc-reach-opposite-conclusions-on-amgen-s-pcsk9-antibody-patent-validity 2025-07-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/ppp2r1a-mutations-predict-improved-survival-after-cancer-immunotherapy-in-ovarian-clear-cell-carcinoma 2025-07-02T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/news/fidelio-capital-acquires-majority-stake-in-alphalyse-to-expand-lc-ms-host-cell-protein-testing-globally 2025-07-02T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/organon-discontinues-endometriosis-drug-og-6219-after-phase-ii-trial-failure 2025-07-02T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-s-bat4406f-achieves-early-trial-success-in-rare-neurological-disorder-nmosd 2025-07-02T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/primo-biotechnology-raises-nt-220m-series-a-to-advance-radioligand-theranostics-platform 2025-07-02T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-launches-commercial-sales-of-vescell-stem-cell-therapy-in-florida-under-new-legislation 2025-07-02T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-receives-fda-approval-for-tyzavantm-first-ready-to-infuse-vancomycin-formulation-for-sepsis-treatment 2025-07-02T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/kim-1-emerges-as-promising-prognostic-biomarker-in-advanced-renal-cell-carcinoma 2025-07-02T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-completes-enrollment-in-global-phase-iii-trial-for-blood-brain-barrier-penetrating-hunter-syndrome-therapy 2025-07-02T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-completes-enrollment-in-phase-3-phoenix-trial-for-geographic-atrophy-treatment 2025-07-02T16:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/capsule-sponge-test-shows-promise-as-alternative-to-endoscopy-for-barrett-s-esophagus-monitoring 2025-07-02T16:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-reverses-patent-board-ruling-on-eye-redness-treatment-strengthens-brimonidine-patent-protection 2025-07-02T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/rbc-capital-raises-xenon-pharmaceuticals-price-target-to-57-based-on-phase-iii-epilepsy-drug-optimism 2025-07-02T13:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-integrates-clonoseq-mrd-testing-into-flatiron-health-s-oncoemr-platform 2025-07-02T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/australia-opens-first-antibody-drug-conjugate-manufacturing-facility-to-advance-precision-cancer-treatment 2025-07-02T08:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/china-launches-commercial-insurance-catalog-to-accelerate-innovative-drug-development 2025-07-02T04:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-races-to-launch-first-generic-semaglutide-in-canada-as-wegovy-patents-expire 2025-07-02T04:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-cah-treatment-portfolio-with-long-acting-injectable-therapy 2025-07-02T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-engineers-develop-first-immunocompetent-leukemia-on-a-chip-device-to-advance-car-t-cell-therapy-testing 2025-07-02T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/catalio-capital-closes-400m-fund-iv-to-back-healthcare-and-biotech-companies-amid-market-downturn 2025-07-02T02:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-ceo-reportedly-considers-us-stock-listing-move-amid-uk-regulatory-frustrations 2025-07-02T02:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-approaches-critical-fda-decision-for-lytenava-as-european-launch-validates-market-potential 2025-07-02T01:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/simtra-biopharma-solutions-completes-major-facility-expansion-in-germany-to-meet-growing-injectable-therapeutics-demand 2025-07-02T01:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/first-oral-drug-ma-5-shows-promise-for-rare-barth-syndrome-in-preclinical-studies 2025-07-02T01:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-secures-5-million-private-placement-to-advance-cancer-therapy-development 2025-07-02T00:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-secures-5m-funding-for-cancer-therapy-development-stock-surges-55 2025-07-02T00:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/house-republicans-subpoena-former-pfizer-executive-over-alleged-covid-19-vaccine-trial-delays 2025-07-02T00:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-submits-fda-510-k-application-for-home-use-of-arc-ex-spinal-cord-stimulation-system 2025-07-02T00:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/oruka-therapeutics-promotes-laura-sandler-to-coo-as-company-advances-novel-psoriasis-pipeline 2025-07-01T23:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/quiver-bioscience-secures-2-15m-nih-grant-to-develop-ai-powered-cns-drug-safety-platform 2025-07-01T23:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-advances-gene-therapy-pipeline-with-fda-rmat-designation-and-pivotal-trial-progress 2025-07-01T23:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/inhalation-sciences-secures-recurring-orders-from-global-pharma-customer-strengthening-preclinical-research-platform 2025-07-01T22:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-mrna-vaccine-shows-promise-against-deadly-elephant-virus-in-first-real-world-test 2025-07-01T21:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/carthera-s-sonocloud-system-receives-ema-orphan-medical-device-endorsement-for-brain-tumor-treatment 2025-07-01T20:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-completes-80-million-acquisition-of-mattek-to-advance-3d-cell-model-technology 2025-07-01T20:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-secures-202m-licensing-deal-with-henlius-for-novel-cd47-targeting-cancer-immunotherapy 2025-07-01T20:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/rush-university-medical-center-launches-first-ever-apple-vision-pro-colonoscopy-study-with-ai-integration 2025-07-01T20:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-launches-precision-medicine-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-07-01T20:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/feliqs-secures-9-million-series-a-to-advance-novel-rop-prevention-therapy-flq-101 2025-07-01T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-advances-pembrolizumab-biosimilar-development-as-herceptin-copy-nears-european-launch 2025-07-01T19:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-strengthens-leadership-team-with-three-key-executive-appointments 2025-07-01T19:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/sonoclear-system-receives-fda-breakthrough-device-designation-for-enhanced-brain-tumor-surgery-imaging 2025-07-01T19:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/senzime-secures-major-u-s-hospital-contract-and-new-patent-for-tetragraph-neuromuscular-monitoring-system 2025-07-01T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-xdc-completes-singapore-manufacturing-facility-expanding-global-bioconjugate-production-network 2025-07-01T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-advances-dpx-platform-as-alternative-to-lipid-nanoparticles-for-mrna-vaccine-delivery 2025-07-01T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-bioscience-s-hro350-shows-promise-in-phase-2b-psoriasis-trial-despite-missing-primary-endpoint 2025-07-01T17:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/inmagene-initiates-phase-2b-trial-of-img-007-anti-ox40-antibody-for-moderate-to-severe-atopic-dermatitis 2025-07-01T17:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/adiposs-secures-chf-4-million-series-a-to-advance-brown-fat-imaging-technology-for-cancer-treatment-prediction 2025-07-01T17:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-secures-14-7m-eic-funding-to-advance-single-cell-protein-interactome-analysis-platform 2025-07-01T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/ns-pharma-and-boston-children-s-hospital-form-strategic-alliance-to-advance-rare-disease-therapies 2025-07-01T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-terminates-phase-ii-cd47-trial-in-blood-cancer-due-to-recruitment-challenges 2025-07-01T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-completes-manufacturing-transfer-of-synthetic-hypericin-for-rare-skin-cancer-treatment 2025-07-01T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/pharmnovo-advances-non-addictive-neuropathic-pain-drug-pn6047-with-phase-2-trial-application 2025-07-01T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-invests-1-1-billion-in-european-biosimilar-manufacturing-hub-to-capture-222-billion-market-opportunity 2025-07-01T17:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-partners-with-unnatural-products-in-1-5-billion-macrocyclic-peptide-deal 2025-07-01T16:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-and-bioeq-ag-partner-to-bring-ranibizumab-biosimilar-to-sub-saharan-africa 2025-07-01T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/arthrosi-therapeutics-achieves-rapid-enrollment-milestone-in-phase-3-gout-trial-for-pozdeutinurad 2025-07-01T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/imagene-ai-secures-23m-series-b-led-by-larry-ellison-to-advance-multi-modal-foundation-models-for-precision-medicine 2025-07-01T16:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-raises-20-million-to-advance-concussion-treatment-clinical-trials 2025-07-01T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/intrabio-completes-phase-iii-recruitment-for-ataxia-telangiectasia-treatment-in-record-time 2025-07-01T16:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-secures-nasdaq-listing-extension-to-advance-phase-3-ovarian-cancer-immunotherapy 2025-07-01T16:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/oncternal-therapeutics-sells-ror1-targeting-programs-to-ho-ola-therapeutics-for-68-million-deal 2025-07-01T12:56:40+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-launches-global-phase-3-trial-for-ycanth-in-common-warts-targeting-22-million-us-patients 2025-07-01T12:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/ribociclib-kisqali-added-to-pbs-for-early-stage-breast-cancer-patients-in-australia 2025-07-01T12:55:35+00:00 hourly 0.9 https://trial.medpath.com/news/lutroo-imaging-initiates-first-in-human-trial-of-radiocainetm-pet-tracer-for-pain-visualization 2025-07-01T12:54:43+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-licenses-abeona-s-aav204-gene-therapy-platform-for-retinal-disease-treatment 2025-07-01T12:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-secures-50-million-private-placement-to-advance-psychedelic-mental-health-therapies 2025-07-01T12:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/apellis-secures-300-million-in-non-dilutive-financing-through-sobi-royalty-agreement-for-rare-kidney-disease-therapy 2025-07-01T12:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharmaceutical-secures-nmpa-approval-for-jak1-inhibitor-ivarmacitinib-in-severe-alopecia-areata 2025-07-01T12:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/empnia-receives-fda-clearance-for-emotus-respiratory-motion-management-system-in-radiation-therapy 2025-07-01T12:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-reports-3-year-survival-in-glioblastoma-patients-with-temferon-cell-therapy 2025-07-01T12:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/sigvotatug-vedotin-shows-promise-in-nsclc-as-novel-integrin-beta-6-targeted-adc-advances-to-phase-3 2025-07-01T12:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-strengthens-leadership-team-with-appointment-of-chief-medical-officer-and-business-development-advisor 2025-07-01T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/healx-partners-with-sci-ventures-in-2m-ai-driven-initiative-to-develop-spinal-cord-injury-treatments 2025-07-01T09:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/drc-medicine-announces-422-million-spac-merger-to-advance-therapeutic-mask-technology-and-parkinson-s-drug-pipeline 2025-07-01T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/capsule-sponge-test-combined-with-biomarkers-shows-promise-for-barrett-esophagus-risk-stratification 2025-07-01T04:53:29+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-raises-650-million-through-convertible-notes-to-advance-ai-driven-precision-medicine-platform 2025-07-01T04:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-iks014-her2-targeted-adc-enabling-us-clinical-trial-expansion 2025-07-01T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/third-line-mcrc-treatment-landscape-evolves-with-multiple-sequential-options-offering-modest-survival-benefits 2025-07-01T02:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/ambroxol-shows-promise-in-slowing-parkinson-s-disease-dementia-in-phase-ii-clinical-trial 2025-07-01T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-1-trial-for-long-acting-cah-treatment-nbip-01435 2025-07-01T00:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/chemoimmunotherapy-shows-limited-efficacy-in-younger-patients-with-extensive-stage-small-cell-lung-cancer 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-face-massive-revenue-losses-as-patent-cliff-hits-key-blockbusters 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapy-immunotherapy-combinations-show-promise-for-enhanced-cancer-treatment-through-abscopal-effects 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ich-releases-draft-e20-guideline-on-adaptive-clinical-trial-designs-for-global-harmonization 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-phase-1b-2-trial-of-dual-car-t-therapy-azd0120-for-refractory-systemic-lupus-erythematosus 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/somai-pharmaceuticals-acquires-rpk-biopharma-strengthening-global-cannabis-manufacturing-leadership 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-cardiovascular-risks-for-hyperkalemia-drug-sodium-zirconium-cyclosilicate 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-advances-pn-477-triple-agonist-for-obesity-treatment-targeting-same-mechanism-as-eli-lilly-s-retatrutide 2025-06-30T23:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-stock-surges-over-130-following-positive-preclinical-depression-data-and-first-in-human-pain-trial-results 2025-06-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-new-safety-warnings-for-adhd-stimulants-in-children-under-six 2025-06-30T21:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/partial-breast-radiation-proves-non-inferior-to-whole-breast-treatment-in-10-year-follow-up-of-uk-import-low-trial 2025-06-30T20:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-enrolls-first-patient-in-novel-carotid-stent-trial-targeting-stroke-prevention 2025-06-30T20:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-shows-promise-for-autoimmune-disease-treatment-in-preclinical-studies 2025-06-30T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-screen-reveals-key-to-enhancing-rna-drug-efficacy-through-endosomal-transport-modulation 2025-06-30T19:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/zilucoplan-shows-sustained-efficacy-and-steroid-sparing-benefits-in-long-term-myasthenia-gravis-treatment 2025-06-30T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-restructures-operations-to-focus-on-synthetic-dna-manufacturing-for-gene-therapies 2025-06-30T18:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-acquires-full-us-rights-to-ameluz-and-rhodoled-secures-11m-funding 2025-06-30T16:45:50+00:00 hourly 0.9 https://trial.medpath.com/news/cd19-car-t-cell-therapy-shows-promise-in-relapsed-t-8-21-aml-despite-short-term-remission 2025-06-30T16:43:27+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-secures-40-million-amed-grant-to-advance-dual-antigen-allogeneic-car-t-therapy-for-b-cell-lymphomas 2025-06-30T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-capstan-therapeutics-for-2-1-billion-to-advance-in-vivo-car-t-technology-for-autoimmune-diseases 2025-06-30T16:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-plus-bevacizumab-emerges-as-optimal-first-line-treatment-for-advanced-hepatocellular-carcinoma 2025-06-30T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-initiates-phase-1b-trial-of-long-acting-hsv-helicase-primase-inhibitor-abi-1179 2025-06-30T16:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/logicflo-ai-secures-2-7m-to-deploy-ai-agents-across-life-sciences-operations 2025-06-30T16:36:07+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-in-vivo-car-t-developer-capstan-therapeutics-for-up-to-2-1-billion 2025-06-30T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-mixed-benefits-of-first-line-vs-second-line-cdk4-6-inhibitor-therapy-in-hr-her2-metastatic-breast-cancer 2025-06-30T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-bispecific-antibody-success-from-3m-startup-to-15b-global-biotech-leader 2025-06-30T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-fusion-and-curadh-form-strategic-partnership-to-advance-astatine-211-radiopharmaceuticals 2025-06-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-and-summit-therapeutics-launch-clinical-collaboration-to-test-ras-inhibitor-combinations-with-bispecific-antibody 2025-06-30T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-toby-s-ai-powered-urine-test-for-bladder-cancer-detection 2025-06-30T16:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-ai-submits-de-novo-fda-application-for-ai-powered-burn-assessment-device 2025-06-30T16:30:48+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-pmprb-releases-new-drug-price-review-guidelines-implementing-two-step-process-starting-january-2026 2025-06-30T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/portal-biotech-secures-35m-series-a-to-commercialize-world-s-first-full-length-single-molecule-protein-sequencer 2025-06-30T16:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-takeda-s-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-for-primary-immunodeficiency 2025-06-30T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-review-of-skinvive-by-juvederm-for-neck-line-treatment-expansion 2025-06-30T16:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-bemarituzumab-shows-significant-survival-benefit-in-phase-3-gastric-cancer-trial 2025-06-30T16:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/dual-ctla-4-and-pd-1-blockade-shows-superior-efficacy-in-melanoma-brain-metastases 2025-06-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-vorinostat-combination-shows-promise-in-recurrent-squamous-cell-carcinoma 2025-06-30T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/news/laverock-therapeutics-raises-ps20m-in-expanded-seed-funding-reports-positive-data-for-cancer-cell-therapy-programs 2025-06-30T12:58:38+00:00 hourly 0.9 https://trial.medpath.com/news/vetter-breaks-ground-on-285-million-clinical-manufacturing-facility-in-illinois 2025-06-30T12:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/epigenica-secures-2-2m-to-advance-high-throughput-epigenetic-screening-platform 2025-06-30T12:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-orpathys-tagrisso-combination-for-egfr-mutated-lung-cancer-with-met-amplification 2025-06-30T12:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-appoints-christine-coyne-as-chief-commercial-officer-to-lead-orlynvah-launch 2025-06-30T12:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-secures-300-million-royalty-financing-to-support-attr-cm-drug-launch 2025-06-30T12:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-launches-wuxihigh22-0-platform-achieving-record-230-mg-ml-protein-concentrations 2025-06-30T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-s-gedatolisib-shows-promising-results-in-prostate-and-breast-cancer-trials 2025-06-30T12:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-completes-200-patient-study-revealing-40-mortality-rate-in-acute-melioidosis 2025-06-30T12:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-subsidiary-receives-fda-establishment-inspection-report-following-new-york-facility-review 2025-06-30T08:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-therapeutics-develops-oral-liquid-formulation-of-nuz-001-for-als-patients-with-swallowing-difficulties 2025-06-30T08:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/faron-research-reveals-novel-immune-evasion-mechanism-validates-bexmarilimab-s-therapeutic-approach 2025-06-30T08:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/esteve-acquires-caprelsa-rights-from-sanofi-to-expand-rare-cancer-treatment-portfolio 2025-06-30T08:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/roche-announces-leadership-changes-as-head-of-pharma-r-d-hans-clevers-retires 2025-06-30T08:53:30+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-advances-argx-119-to-registrational-study-for-ultra-rare-congenital-myasthenic-syndromes 2025-06-30T08:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/stalicla-secures-chf-2-million-financing-from-addex-therapeutics-to-advance-precision-medicine-for-autism-and-neurodevelopmental-disorders 2025-06-30T08:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-advances-gene-therapy-manufacturing-for-als-treatment 2025-06-30T08:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/investor-challenges-avadel-board-over-alleged-lumryz-launch-mismanagement 2025-06-30T04:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-s-intranasal-erectile-dysfunction-treatment-spontan-demonstrates-470-faster-absorption-in-pivotal-study 2025-06-30T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-reports-mixed-phase-2b-results-as-bpl-003-succeeds-while-inidascamine-falls-short 2025-06-30T04:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-rmit-developed-ingestible-gas-capsule-for-diagnosing-gut-motility-disorders 2025-06-30T04:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurinia-s-aritinercept-shows-promising-safety-and-efficacy-in-phase-1-trial-for-autoimmune-diseases 2025-06-30T04:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-molecular-imaging-reveals-critical-immune-response-patterns-in-pig-to-human-kidney-xenotransplantation 2025-06-30T00:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/remdesivir-shows-modest-reduction-in-long-covid-risk-among-hospitalized-patients 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-medication-benefits-diminish-as-prescription-rates-rise-swedish-study-reveals 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-year-us-safety-data-confirms-brodalumab-s-stable-risk-profile-in-psoriasis-treatment 2025-06-29T20:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/brain-imaging-reveals-why-parkinson-s-drug-levodopa-fails-some-patients 2025-06-29T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/metabolomics-study-identifies-angiotensin-iv-as-highly-accurate-biomarker-for-tuberculosis-diagnosis 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-immunotherapy-advances-target-uveal-melanoma-s-resistance-mechanisms 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-voranigo-vorasidenib-as-first-targeted-therapy-for-idh-mutant-glioma 2025-06-29T12:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/karnataka-government-seeks-dcgi-investigation-into-hcg-clinical-trial-ethics-violations 2025-06-29T05:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/trichoscopy-emerges-as-key-diagnostic-tool-for-early-detection-and-differentiation-of-alopecia-types 2025-06-29T02:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapy-linked-to-8-9-fold-increased-risk-of-secondary-t-cell-lymphoma-in-global-study 2025-06-29T01:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/icon-group-invests-18-7-million-in-advanced-radiotherapy-technology-partnership-with-varian-to-address-uk-cancer-care-gap 2025-06-29T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/cansino-biologics-launches-phase-3-covid-19-vaccine-trial-in-pakistan-despite-declining-case-numbers 2025-06-29T01:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-achieve-3d-printing-breakthrough-for-type-1-diabetes-treatment-using-functional-human-islets 2025-06-29T00:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-files-for-secondary-sgx-listing-to-expand-southeast-asia-operations 2025-06-28T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-secures-600-private-placement-to-advance-multiple-sclerosis-drug-development 2025-06-28T20:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-raises-19m-to-advance-alzheimer-s-neuroinflammation-therapy-ahead-of-pivotal-trial-results 2025-06-28T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-partners-with-pfizer-and-lumina-in-fibre-consortium-to-transform-fibrotic-disease-clinical-trials 2025-06-28T17:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rejects-johnson-johnson-s-340b-drug-pricing-rebate-model 2025-06-28T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-market-sees-780-investment-surge-following-leqembi-and-kisunla-approvals 2025-06-28T17:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-pharmaceuticals-commits-1-billion-to-expand-us-generic-medicine-manufacturing-through-2030 2025-06-28T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/india-mandates-digital-only-applications-for-who-gmp-and-copp-certificates-through-ondls-portal 2025-06-28T13:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/iridex-enrolls-first-patient-in-dame-trial-testing-micropulse-laser-as-adjunct-to-anti-vegf-therapy-for-severe-diabetic-macular-edema 2025-06-28T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-recalls-over-4600-bottles-of-acetaminophen-in-us-due-to-tablet-discoloration 2025-06-28T13:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/cook-medical-issues-class-i-recall-of-beacon-tip-catheters-following-tip-separation-injuries 2025-06-28T11:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/torrent-pharma-advances-2-4-billion-acquisition-of-jb-chemicals-in-major-industry-consolidation-move 2025-06-28T08:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/natural-polymers-emerge-as-promising-platform-for-advanced-insulin-delivery-systems 2025-06-28T08:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-corporation-to-acquire-turnstone-biologics-for-0-34-per-share-plus-contingent-value-rights 2025-06-28T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/urine-dna-test-predicts-bladder-cancer-recurrence-after-immunotherapy-treatment 2025-06-28T05:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/selinexor-maintenance-therapy-shows-sustained-benefit-in-tp53-wild-type-advanced-endometrial-cancer 2025-06-28T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-daraxonrasib-in-kras-mutated-pancreatic-cancer 2025-06-28T04:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/paralyzed-veteran-becomes-first-neuralink-brain-computer-interface-recipient-at-university-of-miami 2025-06-28T04:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-update-treatment-sequencing-for-metastatic-gastrointestinal-stromal-tumors 2025-06-28T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-senescence-gene-signature-reveals-new-biomarkers-for-idiopathic-pulmonary-fibrosis 2025-06-28T03:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/bcma-targeted-car-t-therapy-achieves-96-3-response-rate-in-relapsed-multiple-myeloma-study 2025-06-28T01:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gamifant-as-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease 2025-06-28T00:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-reports-75-pain-reduction-in-pediatric-acute-pain-study-eyes-us-launch-by-end-2025 2025-06-28T00:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/retinalgenix-partners-with-labcorp-to-launch-dna-gps-platform-for-genetic-and-retinal-disease-screening 2025-06-27T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/prd-therapeutics-initiates-first-in-human-trial-of-soat2-selective-inhibitor-prd001-for-rare-cholesterol-disorders 2025-06-27T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/bioporto-launches-pronephro-aki-diagnostic-test-in-us-market-through-roche-partnership 2025-06-27T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-tovorafenib-offers-new-treatment-option-for-pediatric-low-grade-glioma-with-braf-v600-mutations 2025-06-27T20:46:59+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-esophageal-cancer-organ-chips-accurately-predict-chemotherapy-response-in-clinical-study 2025-06-27T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-normalizes-brain-blood-flow-in-sickle-cell-disease-patients-reducing-stroke-risk 2025-06-27T20:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-vms-therapy-shows-early-promise-in-improving-quality-of-life-for-breast-cancer-patients 2025-06-27T16:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-divests-european-orladeyo-rights-for-264-million-to-achieve-debt-free-status 2025-06-27T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/stentit-initiates-first-in-human-trial-of-regenerative-stent-for-chronic-limb-threatening-ischemia 2025-06-27T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-navigates-eylea-decline-with-pipeline-diversification-and-regulatory-wins 2025-06-27T16:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-achieves-100-survival-rate-with-novel-t-cell-engagers-in-pancreatic-cancer-preclinical-study 2025-06-27T16:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-maintains-record-breaking-approval-pace-despite-organizational-upheaval-highlighting-three-breakthrough-therapies 2025-06-27T16:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-launches-fast-track-clinical-trial-review-to-accelerate-patient-access-to-life-saving-treatments 2025-06-27T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/transthera-s-tinengotinib-shows-promise-against-fgfr-resistant-cholangiocarcinoma-in-annals-of-oncology-study 2025-06-27T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-s-sgr-1505-receives-fda-fast-track-designation-for-relapsed-waldenstrom-macroglobulinemia 2025-06-27T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-and-gsk-pledge-to-cut-malaria-vaccine-price-by-more-than-half-to-under-5-by-2028 2025-06-27T15:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/tc-biopharm-leads-gamma-delta-t-cell-therapy-development-with-over-25-clinical-programs-worldwide 2025-06-27T15:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/complement-based-drug-development-gains-momentum-following-fda-approvals-and-pipeline-advances 2025-06-27T14:40:59+00:00 hourly 0.9 https://trial.medpath.com/news/indian-crdmos-gain-momentum-as-global-pharma-diversifies-manufacturing-operations 2025-06-27T13:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/bone-biologics-files-patent-application-for-novel-nell-1-protein-technology-in-spine-fusion 2025-06-27T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-regulatory-barriers-for-bristol-myers-squibb-s-car-t-cell-therapies-expanding-patient-access 2025-06-27T13:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/sms-pharmaceuticals-passes-second-usfda-inspection-with-zero-observations-at-telangana-analytical-laboratory 2025-06-27T13:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-advisors-completes-7-billion-acquisition-of-crispr-solutions-leader-synthego 2025-06-27T10:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/glofitamab-pirtobrutinib-combination-shows-77-response-rate-in-btk-inhibitor-exposed-mantle-cell-lymphoma 2025-06-27T09:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-first-three-patients-treated-and-indian-regulatory-approval 2025-06-27T08:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-streamlined-access-for-bristol-myers-squibb-car-t-cell-therapies 2025-06-27T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-significant-neutropenia-risk-variations-among-adc-therapies 2025-06-27T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-pharma-initiates-phase-iii-trial-of-art-123-for-chemotherapy-induced-peripheral-neuropathy-prevention 2025-06-27T08:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-fenfluramine-achieves-positive-phase-3-results-in-ultra-rare-cdkl5-deficiency-disorder 2025-06-27T08:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-amplifies-medtronic-recall-of-bravo-acid-reflux-test-capsules-after-33-serious-injuries 2025-06-27T06:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-accelerated-approval-for-edgewise-s-sevasemten-in-becker-muscular-dystrophy 2025-06-27T04:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/zenocutuzumab-achieves-30-response-rate-in-nrg1-fusion-positive-solid-tumors-receives-fda-approval 2025-06-27T04:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/orano-med-expands-texas-r-d-center-to-advance-lead-212-targeted-alpha-therapies 2025-06-27T03:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-linked-to-increased-red-blood-cell-counts-but-no-thrombotic-risk-in-type-2-diabetes-patients 2025-06-27T03:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-model-achieves-96-accuracy-in-predicting-breast-cancer-treatment-related-cardiac-events 2025-06-27T02:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/tilray-medical-publishes-pharmacokinetic-study-comparing-oral-and-oromucosal-cannabis-formulations 2025-06-27T00:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/eva-pharma-establishes-eighth-global-office-in-hangzhou-s-biopharma-town-to-advance-cell-and-gene-therapy-innovation 2025-06-27T00:52:18+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-escalates-patent-defense-with-three-new-biosimilar-lawsuits-targeting-denosumab-competitors 2025-06-27T00:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-neopred-predicts-lung-cancer-treatment-response-before-surgery-using-dual-phase-ct-imaging 2025-06-27T00:51:14+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-submits-first-clinical-trial-application-for-rna-editing-platform-with-ax-0810-targeting-cholestatic-liver-disease 2025-06-27T00:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-sympatico-study-shows-promising-first-line-ibrutinib-venetoclax-combination-for-older-mcl-patients 2025-06-27T00:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-patient-receives-breakthrough-treatment-for-ultra-rare-apds-immune-disorder 2025-06-27T00:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/modus-therapeutics-secures-sek-28-3-million-in-fully-subscribed-rights-issue-to-advance-sevuparin-development 2025-06-27T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-secures-4-4-million-in-funding-to-advance-clinical-trials-for-cancer-and-pain-therapeutics 2025-06-27T00:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-appoints-scott-madel-as-chief-commercial-officer-to-drive-infoods-ibs-test-commercialization 2025-06-27T00:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-courts-uphold-medicare-drug-price-negotiation-program-against-pharmaceutical-industry-challenges 2025-06-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/budget-impact-analysis-shows-revumenib-cost-neutral-for-health-plans-despite-high-specialty-drug-costs 2025-06-26T23:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/prokaryotics-secures-global-rights-to-novel-gram-negative-antibiotic-potentiator-nab741 2025-06-26T22:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-commits-eur129-million-to-expand-irish-operations-with-focus-on-biologics-manufacturing 2025-06-26T21:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/theracosbio-partners-with-publix-to-expand-access-to-low-cost-sglt2-inhibitor-brenzavvy-for-type-2-diabetes 2025-06-26T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-names-bill-meury-as-new-ceo-replacing-11-year-veteran-herve-hoppenot 2025-06-26T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-launches-journavx-first-non-opioid-acute-pain-treatment-in-over-two-decades 2025-06-26T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-siemens-healthineers-first-virtually-helium-free-1-5t-mri-scanner 2025-06-26T20:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/ku-medical-center-receives-31-million-nih-grant-to-expand-pediatric-clinical-trial-access-in-underserved-areas 2025-06-26T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/tfs-healthscience-demonstrates-specialized-capabilities-in-complex-ophthalmology-trials-for-geographic-atrophy-and-dry-eye-disease 2025-06-26T20:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-appoints-than-powell-as-chief-business-officer-to-lead-alzheimer-s-and-hlhs-program-strategy 2025-06-26T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/angel-yeast-advances-biomanufacturing-with-new-biotechnology-park-set-for-september-launch 2025-06-26T18:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/embolization-inc-receives-fda-clearance-for-novel-nonmetal-vascular-coil-device 2025-06-26T18:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/cellarity-initiates-phase-1-trial-of-cly-124-first-in-class-oral-therapy-for-sickle-cell-disease 2025-06-26T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-shares-plunge-60-despite-positive-mash-trial-results-as-fibrosis-endpoint-falls-short 2025-06-26T18:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/provectus-pv-10-immunotherapy-shows-promise-in-head-and-neck-cancer-through-novel-cell-death-mechanism 2025-06-26T17:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-expands-public-coverage-of-xtandi-for-high-risk-prostate-cancer-patients 2025-06-26T16:55:02+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-successfully-transfers-lumevoq-manufacturing-to-catalent-for-lhon-gene-therapy 2025-06-26T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-shows-promise-for-early-detection-of-heart-transplant-rejection-could-replace-80-of-invasive-biopsies 2025-06-26T16:54:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-once-daily-nebulized-lama-for-copd-triggering-7-5m-milestone-for-theravance 2025-06-26T16:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-s-certepetide-shows-promising-results-in-phase-2b-pancreatic-cancer-trial 2025-06-26T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-scientists-develop-single-shot-malaria-vaccine-using-programmable-microcapsule-technology 2025-06-26T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/alebund-s-ap301-meets-primary-endpoint-in-phase-3-trial-for-hyperphosphatemia-in-dialysis-patients 2025-06-26T16:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-lipid-nanoparticles-show-enhanced-extrahepatic-mrna-delivery-and-improved-stability 2025-06-26T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-prepares-cnside-diagnostics-platform-for-u-s-commercial-launch-in-second-half-2025 2025-06-26T16:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/sysmex-america-secures-fda-clearance-for-cn-6000-automated-blood-coagulation-analyzer 2025-06-26T16:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/portable-gene-therapy-device-could-revolutionize-on-demand-personalized-medicine-for-rare-diseases 2025-06-26T16:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/lipocine-initiates-phase-3-trial-for-oral-brexanolone-in-postpartum-depression 2025-06-26T16:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/xeomin-receives-first-ever-approval-in-japan-for-chronic-sialorrhea-treatment 2025-06-26T16:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhanced-labeling-for-endari-based-on-post-marketing-pharmacokinetic-data 2025-06-26T16:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/imcd-acquires-trichem-to-strengthen-pharmaceutical-supply-chain-in-india-s-generic-drug-market 2025-06-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zyversa-therapeutics-initiates-phase-2a-trial-for-first-in-class-diabetic-kidney-disease-treatment-var-200 2025-06-26T15:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/c7-neurotomy-combined-with-speech-therapy-shows-superior-results-for-chronic-post-stroke-aphasia 2025-06-26T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/profound-therapeutics-partners-with-novartis-in-775m-cardiovascular-drug-discovery-deal 2025-06-26T12:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-demonstrates-selumetinib-efficacy-in-adults-with-neurofibromatosis-type-1 2025-06-26T12:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-sells-ganaxolone-royalty-rights-to-immedica-pharma-for-7-million 2025-06-26T11:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/former-pfizer-cso-mikael-dolsten-joins-two-biotech-boards-advancing-gene-editing-and-mast-cell-therapeutics 2025-06-26T11:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-only-8-of-patients-continue-glp-1-obesity-treatment-after-three-years 2025-06-26T11:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/invetech-and-aicella-form-strategic-partnership-to-integrate-ai-into-cell-therapy-manufacturing 2025-06-26T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-raises-250-8-million-to-advance-targeted-protein-degradation-pipeline 2025-06-26T10:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-independent-drug-regulatory-authority-by-end-2026-ending-reliance-on-foreign-approvals 2025-06-26T09:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/teva-partners-with-formycon-to-commercialize-stelara-biosimilar-fymskina-in-germany 2025-06-26T09:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/ambry-genetics-care-program-achieves-99-5-accuracy-in-hereditary-cancer-risk-assessment 2025-06-26T09:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/2-million-donation-accelerates-car-t-cell-immunotherapy-trials-for-end-stage-cancer-patients-in-canada 2025-06-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-expands-u-s-operations-with-new-houston-facility-to-advance-novel-neutrophil-immunotherapy 2025-06-26T07:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/updated-covid-19-vaccines-show-strong-protection-against-severe-illness-in-comprehensive-cdc-study 2025-06-26T07:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-initiates-first-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women 2025-06-26T07:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/infliximab-biosimilar-adoption-in-pediatric-ibd-reaches-42-by-2023-reveals-regional-disparities 2025-06-26T05:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-acquires-phase-ii-ready-anti-vista-cancer-immunotherapy-hmbd-002-in-290m-deal 2025-06-26T04:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocity-s-sc0062-receives-second-breakthrough-therapy-designation-for-diabetic-kidney-disease-treatment 2025-06-26T04:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-secures-us-patent-for-nnz-2591-in-pitt-hopkins-syndrome-treatment 2025-06-26T04:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-secures-global-rights-to-telitacicept-in-4-billion-deal-with-remegen 2025-06-26T04:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-launches-world-s-first-clinical-trial-testing-thc-cbd-combination-for-canine-osteoarthritis 2025-06-26T04:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/certify-raises-40m-series-b-to-transform-healthcare-provider-data-infrastructure 2025-06-26T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-mycosis-fungoides-treatment-requires-strategic-sequencing-of-hdac-inhibitors-and-targeted-therapies 2025-06-26T03:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/alafair-biosciences-initiates-multi-center-study-of-versawrap-hydrogel-device-for-achilles-tendon-repair 2025-06-26T03:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-s-reconstituted-vaccine-advisory-panel-votes-to-eliminate-thimerosal-from-all-flu-vaccines 2025-06-26T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-initiates-comfort-toddlers-phase-3-study-for-viaskin-peanut-patch-in-young-children 2025-06-26T01:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-partners-with-csl-seqirus-for-exclusive-german-vaccine-distribution-deal 2025-06-26T01:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-to-advance-glioblastoma-drug-development 2025-06-26T00:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/cellugy-secures-eur8-1-million-eu-funding-to-scale-microplastic-alternative-for-cosmetics-industry 2025-06-26T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/metabolics-pharma-s-ent-03-shows-promise-in-phase-1a-trial-for-obesity-and-type-2-diabetes 2025-06-25T23:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/ps7-5-million-longitude-prize-launches-to-accelerate-ai-driven-als-drug-discovery 2025-06-25T22:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/raybiotech-and-venebio-group-form-strategic-partnership-to-accelerate-drug-development-through-integrated-proteomics-and-regulatory-expertise 2025-06-25T22:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/minerva-biotechnologies-achieves-breakthrough-in-patient-derived-stem-cell-manufacturing-for-regenerative-medicine 2025-06-25T21:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/vetigenics-initiates-first-dual-immune-checkpoint-inhibitor-trial-in-dogs-with-solid-tumors 2025-06-25T21:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/jiuzhou-pharma-wins-china-patent-excellence-award-for-breakthrough-synthesis-technology 2025-06-25T21:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-liquid-imatinib-formulation-addresses-critical-dosing-challenges-in-pediatric-cancer-and-dysphagia-patients 2025-06-25T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/exousia-pro-files-patent-for-novel-exosome-loading-technology-targeting-multi-billion-dollar-therapeutic-markets 2025-06-25T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-ipsc-car-nk-cell-therapy-shows-promise-for-autoimmune-disease-treatment 2025-06-25T21:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-receives-fda-clearance-for-incompass-total-ankle-system-integrating-dual-platform-technologies 2025-06-25T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/bryn-pharma-initiates-clinical-trial-for-dual-dose-epinephrine-nasal-spray-to-address-anaphylaxis-treatment-gaps 2025-06-25T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/daily-aspirin-reduces-colorectal-cancer-recurrence-by-55-in-patients-with-specific-genetic-mutations 2025-06-25T18:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/recordati-secures-exclusive-european-rights-to-cardiovascular-drug-vazkepa-in-175-million-deal-with-amarin 2025-06-25T18:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-reports-positive-phase-1b-pet-trial-results-for-pipe-791-in-multiple-sclerosis-and-pulmonary-fibrosis 2025-06-25T18:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-and-entera-bio-advance-first-in-class-oral-dual-glp-1-glucagon-tablet-for-obesity-treatment 2025-06-25T18:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-unveils-12-billion-pipeline-strategy-at-inaugural-r-d-day 2025-06-25T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/q32-bio-names-adrien-sipos-as-interim-cmo-to-lead-alopecia-areata-drug-development 2025-06-25T16:46:17+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-reacquires-global-rights-to-hepatitis-b-rnai-therapy-after-achieving-functional-cure-in-eight-patients 2025-06-25T16:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/dicot-pharma-completes-enrollment-in-phase-2a-erectile-dysfunction-trial-results-expected-by-november-2025 2025-06-25T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-abi-4334-shows-potent-antiviral-activity-in-phase-1b-chronic-hepatitis-b-trial 2025-06-25T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/mira-pharmaceuticals-unveils-preclinical-data-for-skny-1-targeting-obesity-and-smoking-cessation-without-cns-side-effects 2025-06-25T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-sino-universal-pharmaceuticals-to-commercialize-tiotropium-dpi-for-copd-treatment-in-china 2025-06-25T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-launches-ai-powered-vaccine-program-against-group-a-streptococcus 2025-06-25T16:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-detalimogene-for-high-risk-bladder-cancer 2025-06-25T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/angel-pharmaceuticals-receives-china-ind-approval-for-soquelitinib-atopic-dermatitis-trial 2025-06-25T16:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-kymera-s-next-generation-irak4-degrader-kt-485-to-clinical-testing 2025-06-25T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-and-kymera-partner-on-novel-cdk2-molecular-glue-degrader-for-cancer-treatment 2025-06-25T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-initiates-phase-3-trial-for-bat8006-adc-in-platinum-resistant-ovarian-cancer 2025-06-25T16:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/hamlet-biopharma-receives-fda-clearance-for-phase-iii-bladder-cancer-trial-following-successful-regulatory-meeting 2025-06-25T16:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/fraunhofer-researchers-develop-breakthrough-method-to-measure-lung-drug-levels-through-exhaled-breath-particles 2025-06-25T16:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-receives-world-s-first-regulatory-approval-for-non-surgical-permanent-birth-control-system-in-europe 2025-06-25T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/minovia-therapeutics-announces-180m-spac-merger-to-advance-first-in-class-mitochondrial-therapy-platform 2025-06-25T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-and-silo-pharma-form-joint-venture-to-develop-va-licensed-gdnf-based-obesity-treatment 2025-06-25T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/oral-sulopenem-shows-non-inferiority-to-standard-care-in-phase-3-trial-for-uncomplicated-utis 2025-06-25T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/breye-therapeutics-completes-phase-1b-trial-of-oral-danegaptide-for-early-stage-diabetic-retinopathy 2025-06-25T16:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/empatica-launches-world-s-smallest-clinical-trial-wearable-device-for-digital-biomarker-collection 2025-06-25T16:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/botulinum-toxin-combination-therapy-reduces-salivary-gland-toxicity-in-psma-radioligand-treatment 2025-06-25T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-restructures-15-million-equity-financing-to-eliminate-potential-1-5-billion-share-dilution 2025-06-25T14:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/qbiotics-tigilanol-tiglate-achieves-80-response-rate-in-soft-tissue-sarcoma-phase-iia-trial 2025-06-25T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/news/tgfb2-gene-methylation-identified-as-positive-prognostic-biomarker-for-pancreatic-cancer 2025-06-25T12:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-advances-salanersen-to-phase-3-studies-for-spinal-muscular-atrophy-after-promising-results 2025-06-25T12:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/metastx-receives-nci-grant-to-develop-ai-powered-diagnostic-for-metastatic-prostate-cancer-prediction 2025-06-25T12:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/adipose-derived-stem-cell-therapy-achieves-100-hair-regrowth-in-male-mice-for-androgenetic-alopecia 2025-06-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-initiates-intradermal-dosing-in-phase-2-melanoma-trial-reports-strong-early-efficacy-data 2025-06-25T08:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays 2025-06-25T08:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/valorum-biologics-secures-exclusive-rights-to-commercialize-formycon-s-eylea-biosimilar-in-north-america 2025-06-25T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-testing-transforms-breast-cancer-monitoring-and-treatment-selection 2025-06-25T08:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-launches-phase-ii-trials-of-nemolizumab-for-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin 2025-06-25T08:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/lts-and-nualtis-form-strategic-partnership-to-scale-oral-thin-film-drug-delivery-manufacturing 2025-06-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-joins-nurture-aki-consortium-to-advance-multi-omics-research-for-acute-kidney-injury-treatment 2025-06-25T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-researchers-develop-fusion-superkine-therapy-for-glioblastoma-with-novel-blood-brain-barrier-delivery-system 2025-06-25T06:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-launches-low-cost-generic-dimethyl-fumarate-for-multiple-sclerosis-treatment 2025-06-25T06:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-advances-second-generation-cd47-inhibitor-iba101-toward-2027-clinical-trials 2025-06-25T06:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/clinicians-develop-new-monitoring-strategies-for-hypercortisolism-medical-management 2025-06-25T05:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/zetroz-systems-sam-r-2-0-wearable-ultrasound-device-receives-arthritis-foundation-s-ease-of-use-certification 2025-06-25T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/extended-imatinib-therapy-shows-promise-in-high-risk-gist-patients-as-novel-agents-enter-clinical-development 2025-06-25T03:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/bracelet-1-trial-shows-promise-for-oncolytic-virus-pelareorep-in-hr-breast-cancer 2025-06-25T02:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-receives-positive-fda-feedback-for-cue-401-autoimmune-therapy-advances-toward-ind-filing 2025-06-25T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-delivers-first-brain-infused-gene-therapy-for-rare-aadc-deficiency-showing-promising-results-in-three-year-old-patient 2025-06-25T01:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-olomorasib-receives-fda-orphan-drug-designation-for-kras-g12c-mutated-nsclc-treatment 2025-06-25T01:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/trem2-emerges-as-dual-regulator-of-lipid-metabolism-and-immune-response-in-mash 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/guselkumab-demonstrates-high-efficacy-for-psoriasis-treatment-across-all-skin-tones-in-landmark-visible-trial 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-secures-50-million-funding-following-yutrepia-commercial-launch-and-legal-victory 2025-06-24T22:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/fortrea-and-emery-pharma-partner-to-enable-fda-compliant-rifampin-use-in-drug-drug-interaction-studies 2025-06-24T22:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/pathpresenter-receives-fda-510-k-clearance-for-digital-pathology-clinical-viewer 2025-06-24T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/cigna-sues-bristol-myers-squibb-over-alleged-monopoly-practices-for-cancer-drug-pomalyst 2025-06-24T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-receives-who-approval-for-offshore-manufacturing-of-hiv-rapid-test 2025-06-24T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-olanzapine-significantly-reduces-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients 2025-06-24T20:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/curiteva-receives-fda-510-k-clearance-for-first-3d-printed-peek-standalone-spinal-implant 2025-06-24T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/breckenridge-pharmaceutical-receives-fda-approval-for-generic-dehydrated-alcohol-injection-for-hypertrophic-obstructive-cardiomyopathy 2025-06-24T20:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/duvelisib-romidepsin-combination-shows-61-response-rate-in-relapsed-t-cell-lymphomas 2025-06-24T20:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-promise-for-type-1-diabetes-in-off-label-use-study 2025-06-24T20:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/forsight-robotics-raises-125m-series-b-to-advance-oryom-robotic-eye-surgery-platform 2025-06-24T18:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/abridge-secures-300m-series-e-funding-reaches-5-3b-valuation-for-ai-clinical-documentation-platform 2025-06-24T18:50:59+00:00 hourly 0.9 https://trial.medpath.com/news/inventprise-s-novel-covid-19-conjugate-vaccine-shows-broad-protection-against-multiple-variants-in-preclinical-study 2025-06-24T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-appoints-darren-cline-as-chief-commercial-officer-ahead-of-azetukalner-phase-3-data 2025-06-24T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-partners-with-malaysia-s-national-cancer-society-to-launch-biosimilar-access-program 2025-06-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/starton-therapeutics-partners-with-bend-bioscience-to-develop-oral-sustained-release-lenalidomide-for-multiple-myeloma 2025-06-24T17:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/nct-ucc-dresden-launches-phase-2-trial-of-personalized-mrna-vaccine-for-pancreatic-cancer 2025-06-24T17:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/priothera-secures-eur1-7-million-government-funding-to-enhance-car-t-cell-therapy-with-novel-s1p-receptor-modulator 2025-06-24T17:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-faces-patent-challenges-for-diabetes-drug-as-sandoz-seeks-revocation 2025-06-24T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/vector-biomed-partners-with-indian-cancer-hospital-to-deliver-affordable-car-t-therapy-to-rural-populations 2025-06-24T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-acting-drug-chief-jacqueline-corrigan-curay-to-retire-amid-leadership-exodus 2025-06-23T22:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/australian-government-invests-12-million-in-cardiovascular-and-diabetes-medical-technology-innovation 2025-06-23T22:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/sichuan-biokin-s-first-in-class-egfr-her3-adc-advances-to-phase-3-trials-across-multiple-cancer-types 2025-06-23T21:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-acquires-somalogic-for-425-million-to-accelerate-proteomics-and-multiomics-strategy 2025-06-23T21:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/dr-ashleys-limited-acquires-impact-biomedical-in-strategic-reverse-merger-to-accelerate-global-drug-development 2025-06-23T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/lifeplus-achieves-clinical-validation-for-revolutionary-non-invasive-glucose-and-blood-pressure-monitoring-device 2025-06-23T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-base-editing-shows-promise-for-treating-fatal-pediatric-vascular-disease-msmds 2025-06-23T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-names-charles-schoch-as-permanent-cfo-following-successful-86m-capital-raise 2025-06-23T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-completes-enrollment-in-diabetic-foot-ulcer-trial-testing-placental-derived-allograft 2025-06-23T20:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-s-phexxi-hormone-free-contraceptive-seeks-regulatory-approval-in-uae-through-strategic-partnership 2025-06-23T20:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biomedica-achieves-full-ownership-of-us-subsidiary-to-strengthen-global-gene-therapy-manufacturing-network 2025-06-23T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-lag-behind-clinical-practice-as-oncologists-increasingly-adopt-ctdna-testing 2025-06-23T18:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/laekna-s-lae102-shows-promising-safety-profile-in-first-in-human-obesity-trial-at-ada-2025 2025-06-23T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-reaches-50-patent-milestone-with-new-epilepsy-and-nicotine-delivery-patents 2025-06-23T16:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/carisma-therapeutics-and-orthocellix-announce-25m-merger-to-advance-phase-3-knee-cartilage-therapy 2025-06-23T16:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/cure-rare-disease-advances-lgmdr9-gene-therapy-following-positive-fda-pre-ind-meeting 2025-06-23T16:55:05+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-acquires-plasma-services-group-to-strengthen-rare-disease-biomarker-supply-chain 2025-06-23T16:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-to-present-phase-2-data-for-arct-810-mrna-therapy-in-rare-genetic-disorder 2025-06-23T16:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-licenses-dual-jak-syk-inhibitor-gusacitinib-from-formation-bio-in-eur545-million-deal 2025-06-23T16:50:27+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-reports-positive-phase-2-results-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2025-06-23T16:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-submits-phase-iii-protocol-for-vafidemstat-in-borderline-personality-disorder-targeting-first-fda-approved-treatment 2025-06-23T16:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/denovo-biopharma-out-licenses-biomarker-guided-depression-drug-db104-to-taiwan-partner 2025-06-23T16:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/viromed-s-cold-plasma-technology-demonstrates-potential-to-prevent-6000-deaths-annually-from-ventilator-associated-pneumonia 2025-06-23T16:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-bone-growth-accelerator-for-spinal-fusion-surgery 2025-06-23T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/vsee-health-selected-for-nih-funded-phase-3-stroke-telerehabilitation-trial-across-29-hospitals 2025-06-23T16:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/angiodynamics-initiates-recover-av-trial-for-pulmonary-embolism-treatment-device 2025-06-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/altrubio-s-altb-268-shows-promise-in-preclinical-models-of-inflammatory-diseases-supporting-phase-2-uc-trial 2025-06-23T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/new-analysis-shows-radicava-ors-extends-survival-and-slows-functional-decline-in-als-patients 2025-06-23T13:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-strategies-and-adverse-event-management-transform-mcrpc-care 2025-06-23T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/monument-therapeutics-reports-positive-phase-i-results-for-novel-schizophrenia-cognitive-treatment-mt1988 2025-06-23T13:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/penn-researchers-transform-deadly-aspergillus-fungus-into-potent-anti-leukemia-drug 2025-06-23T13:14:26+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-strengthens-leadership-with-endocrinology-expert-to-advance-hypoparathyroidism-treatment 2025-06-23T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-promise-in-combination-with-glp-1-therapies-for-type-2-diabetes 2025-06-23T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/itm-and-debiopharm-initiate-new-study-arm-for-caix-targeted-theranostic-in-clear-cell-renal-cell-carcinoma 2025-06-23T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-imp761-shows-80-t-cell-suppression-in-phase-i-autoimmune-disease-trial 2025-06-23T13:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/novadip-receives-fda-rmat-designation-for-nvd003-regenerative-therapy-in-rare-pediatric-bone-disease 2025-06-23T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/spanish-researchers-develop-dna-test-to-predict-chemotherapy-resistance-clinical-trials-set-for-2026 2025-06-23T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-alvotech-s-biosimilar-to-eylea-for-eye-disorders 2025-06-23T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-ceo-returns-to-drive-us-expansion-with-vitiligo-treatment-approval-strategy 2025-06-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-launches-feasibility-study-for-oral-dissolvable-film-semaglutide-delivery 2025-06-23T13:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-completes-enrollment-of-phase-3-trial-for-once-daily-oral-pah-treatment-ralinepag 2025-06-23T13:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-and-ono-pharmaceutical-form-strategic-alliance-for-povetacicept-development-in-japan-and-south-korea 2025-06-23T13:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-quviviq-receives-approval-in-china-for-insomnia-treatment-through-simcere-partnership 2025-06-23T10:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/progenis-pharmaceuticals-secures-mtpconnect-funding-for-novel-rna-based-type-2-diabetes-treatment 2025-06-23T08:55:42+00:00 hourly 0.9 https://trial.medpath.com/news/carmil2-gain-of-function-mutation-shows-promise-for-next-generation-cancer-immunotherapies 2025-06-23T08:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-nxt007-achieves-zero-bleeds-in-phase-i-ii-hemophilia-a-trial-advances-to-phase-iii 2025-06-23T08:54:46+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-appoints-former-horizon-cfo-aaron-cox-to-lead-strategic-transformation 2025-06-23T08:54:24+00:00 hourly 0.9 https://trial.medpath.com/news/utopia-therapeutics-secures-1-5m-for-novel-obesity-vaccine-ut009 2025-06-23T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/primary-biliary-cholangitis-pipeline-shows-strong-progress-with-multiple-late-stage-therapies-and-recent-fda-approvals 2025-06-23T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-secures-global-rights-to-hbm7020-bcmaxcd3-bispecific-t-cell-engager-for-autoimmune-diseases 2025-06-23T05:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/water-consumption-doubles-diabetes-remission-rates-compared-to-diet-beverages-in-clinical-study 2025-06-23T05:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-secures-100-million-partnership-with-harvard-s-gregory-verdine-to-advance-ai-driven-drug-discovery 2025-06-23T04:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/major-food-companies-eliminate-artificial-dyes-following-fda-push-and-health-concerns 2025-06-23T04:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-launches-next-generation-promarkerd-test-for-early-diabetic-kidney-disease-detection-in-us-market 2025-06-23T00:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-industry-faces-wave-of-strategic-layoffs-as-companies-prioritize-efficiency-and-pipeline-focus 2025-06-23T00:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/sonrotoclax-plus-zanubrutinib-shows-promise-in-relapsed-refractory-mantle-cell-lymphoma-with-78-response-rate 2025-06-22T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-mim8-shows-safe-direct-switch-from-emicizumab-in-phase-3b-hemophilia-a-trial 2025-06-22T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-once-weekly-insulin-efsitora-alfa-achieves-non-inferiority-in-phase-3-trials-reducing-injection-burden-by-300-doses-annually 2025-06-22T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/russia-initiates-phase-i-clinical-trial-for-enteromix-cancer-vaccine-based-on-four-non-pathogenic-viruses 2025-06-22T17:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-oral-diabetes-drug-orforglipron-shows-promise-in-phase-3-trial-offering-alternative-to-injectable-glp-1-therapies 2025-06-22T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-startup-s-urine-based-cancer-test-detects-stage-0-lung-cancer-in-hokkaido-pilot-study 2025-06-22T04:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/magellan-stem-cells-receives-tga-manufacturing-license-advancing-australia-s-cell-therapy-independence 2025-06-22T04:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lenacapavir-for-hiv-prevention-with-99-9-efficacy-but-high-cost-raises-accessibility-concerns-in-india 2025-06-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-advance-nanoscale-drug-delivery-systems-with-targeted-cell-recognition-and-biological-signal-response 2025-06-22T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/abvance-therapeutics-presents-first-human-data-on-fixed-ratio-insulin-glucagon-combination-for-type-1-diabetes 2025-06-22T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-kesimpta-shows-sustained-efficacy-in-multiple-sclerosis-patients-over-seven-years 2025-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radioligand-therapy-177lu-lu-neob-enters-clinical-testing-for-advanced-breast-cancer 2025-06-21T23:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/sai-life-sciences-completes-major-capacity-expansion-at-bidar-manufacturing-facility 2025-06-21T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-delivery-technology-aims-to-prevent-opioid-overdoses-through-controlled-release 2025-06-21T21:05:35+00:00 hourly 0.9